https://trial.medpath.com/news/modex-therapeutics-initiates-first-in-class-trispecific-antibody-trial-for-advanced-cancers 2025-10-28T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modex-therapeutics-initiates-first-in-class-trispecific-antibody-trial-for-advanced-cancers 2025-10-28T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/lumosa-therapeutics-lt3001-shows-promise-in-phase-2b-stroke-trial-with-extended-24-hour-treatment-window 2025-10-28T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumosa-therapeutics-lt3001-shows-promise-in-phase-2b-stroke-trial-with-extended-24-hour-treatment-window 2025-10-28T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/merck-eisai-kidney-cancer-combination-shows-mixed-results-in-phase-3-trial 2025-10-28T17:22:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-eisai-kidney-cancer-combination-shows-mixed-results-in-phase-3-trial 2025-10-28T17:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/yale-researchers-develop-dual-action-mrna-vaccine-for-aggressive-merkel-cell-carcinoma 2025-10-28T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-researchers-develop-dual-action-mrna-vaccine-for-aggressive-merkel-cell-carcinoma 2025-10-28T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-testing-for-non-hallucinogenic-psychedelic-like-depression-treatment 2025-10-28T17:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-at-home-testing-for-non-hallucinogenic-psychedelic-like-depression-treatment 2025-10-28T17:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-neurenati-s-neu-001-for-hirschsprung-disease-treatment 2025-10-28T17:18:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-neurenati-s-neu-001-for-hirschsprung-disease-treatment 2025-10-28T17:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/exousia-pro-receives-fda-orphan-drug-designation-for-exosome-based-glioblastoma-treatment 2025-10-28T17:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exousia-pro-receives-fda-orphan-drug-designation-for-exosome-based-glioblastoma-treatment 2025-10-28T17:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/king-s-college-london-receives-ps2-7m-grant-to-develop-revolutionary-24-hour-nail-fungus-treatment-device 2025-10-28T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/king-s-college-london-receives-ps2-7m-grant-to-develop-revolutionary-24-hour-nail-fungus-treatment-device 2025-10-28T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/integral-molecular-s-membrane-proteome-array-nears-fda-qualification-as-first-nam-for-antibody-specificity-testing 2025-10-28T17:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integral-molecular-s-membrane-proteome-array-nears-fda-qualification-as-first-nam-for-antibody-specificity-testing 2025-10-28T17:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/milliporesigma-partners-with-promega-to-advance-3d-cell-culture-drug-discovery-technologies 2025-10-28T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milliporesigma-partners-with-promega-to-advance-3d-cell-culture-drug-discovery-technologies 2025-10-28T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-s-paridiprubart-shows-25-mortality-reduction-in-phase-3-ards-trial 2025-10-28T17:17:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edesa-biotech-s-paridiprubart-shows-25-mortality-reduction-in-phase-3-ards-trial 2025-10-28T17:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/causeway-therapeutics-reports-positive-phase-2-results-for-tenomir-in-tennis-elbow-treatment 2025-10-28T17:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/causeway-therapeutics-reports-positive-phase-2-results-for-tenomir-in-tennis-elbow-treatment 2025-10-28T17:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-tumor-agnostic-trials-target-her2-positive-cancers-and-p53-mutations-at-esmo-2024 2025-10-28T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-novel-tumor-agnostic-trials-target-her2-positive-cancers-and-p53-mutations-at-esmo-2024 2025-10-28T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/onl-therapeutics-initiates-phase-2-galaxy-trial-for-xelafaslatide-in-geographic-atrophy 2025-10-28T17:15:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onl-therapeutics-initiates-phase-2-galaxy-trial-for-xelafaslatide-in-geographic-atrophy 2025-10-28T17:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cell-death-pathways-transform-melanoma-immunotherapy-targeting-ferroptosis-pyroptosis-and-necroptosis 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cell-death-pathways-transform-melanoma-immunotherapy-targeting-ferroptosis-pyroptosis-and-necroptosis 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-metabolism-emerges-as-key-target-for-cancer-immunotherapy-enhancement 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipid-metabolism-emerges-as-key-target-for-cancer-immunotherapy-enhancement 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sequential-precision-therapy-achieves-79-month-survival-in-afp-producing-gastric-cancer-with-dynamic-her2-conversion 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequential-precision-therapy-achieves-79-month-survival-in-afp-producing-gastric-cancer-with-dynamic-her2-conversion 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/osimertinib-shows-cost-effectiveness-in-china-but-not-us-for-stage-iii-egfr-mutant-nsclc-after-chemoradiotherapy 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osimertinib-shows-cost-effectiveness-in-china-but-not-us-for-stage-iii-egfr-mutant-nsclc-after-chemoradiotherapy 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bat-suspends-vuse-one-vape-launch-as-fda-intensifies-regulatory-crackdown-on-unlicensed-products 2025-10-28T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bat-suspends-vuse-one-vape-launch-as-fda-intensifies-regulatory-crackdown-on-unlicensed-products 2025-10-28T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/domain-therapeutics-initiates-first-in-human-trial-of-dt-7012-anti-ccr8-antibody-for-advanced-solid-tumors 2025-10-28T13:19:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/domain-therapeutics-initiates-first-in-human-trial-of-dt-7012-anti-ccr8-antibody-for-advanced-solid-tumors 2025-10-28T13:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/south-africa-approves-groundbreaking-twice-yearly-hiv-prevention-injection-lenacapavir 2025-10-28T13:19:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-africa-approves-groundbreaking-twice-yearly-hiv-prevention-injection-lenacapavir 2025-10-28T13:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/neom-and-wuxi-apptec-sign-strategic-partnership-to-establish-pharmaceutical-manufacturing-hub-in-saudi-arabia 2025-10-28T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neom-and-wuxi-apptec-sign-strategic-partnership-to-establish-pharmaceutical-manufacturing-hub-in-saudi-arabia 2025-10-28T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-augurex-s-spinestat-test-for-axial-spondyloarthritis-diagnosis 2025-10-28T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-augurex-s-spinestat-test-for-axial-spondyloarthritis-diagnosis 2025-10-28T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-745m-license-deal-for-novel-copd-sirna-therapy-receives-orphan-drug-status-for-cancer-adc 2025-10-28T13:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-secures-745m-license-deal-for-novel-copd-sirna-therapy-receives-orphan-drug-status-for-cancer-adc 2025-10-28T13:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/sudo-biosciences-reports-positive-phase-1-results-for-brain-penetrant-tyk2-inhibitor-sudo-550-in-neuroinflammatory-diseases 2025-10-28T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sudo-biosciences-reports-positive-phase-1-results-for-brain-penetrant-tyk2-inhibitor-sudo-550-in-neuroinflammatory-diseases 2025-10-28T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/organon-ceo-resigns-following-internal-investigation-into-nexplanon-sales-practices 2025-10-28T09:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organon-ceo-resigns-following-internal-investigation-into-nexplanon-sales-practices 2025-10-28T09:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-6-operating-income-growth-driven-by-new-drug-portfolio-performance 2025-10-28T09:21:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-reports-6-operating-income-growth-driven-by-new-drug-portfolio-performance 2025-10-28T09:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/tubulis-secures-361m-series-c-to-advance-napi2b-targeting-adc-for-ovarian-cancer-and-lung-adenocarcinoma 2025-10-28T09:20:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tubulis-secures-361m-series-c-to-advance-napi2b-targeting-adc-for-ovarian-cancer-and-lung-adenocarcinoma 2025-10-28T09:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/japan-grants-orphan-designation-to-otl-200-gene-therapy-for-rare-childhood-disease-mld 2025-10-28T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-grants-orphan-designation-to-otl-200-gene-therapy-for-rare-childhood-disease-mld 2025-10-28T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-s-gazyva-shows-significant-efficacy-in-phase-iii-trial-for-pediatric-idiopathic-nephrotic-syndrome 2025-10-28T09:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-s-gazyva-shows-significant-efficacy-in-phase-iii-trial-for-pediatric-idiopathic-nephrotic-syndrome 2025-10-28T09:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-raises-23-million-to-advance-als-treatment-development 2025-10-28T09:18:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-raises-23-million-to-advance-als-treatment-development 2025-10-28T09:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/rmit-university-develops-molybdenum-oxide-nanodots-that-selectively-target-cancer-cells 2025-10-28T09:18:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rmit-university-develops-molybdenum-oxide-nanodots-that-selectively-target-cancer-cells 2025-10-28T09:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/wits-scientists-develop-breakthrough-nanomedicine-to-combat-drug-resistant-tb-in-heart-and-lungs 2025-10-28T09:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wits-scientists-develop-breakthrough-nanomedicine-to-combat-drug-resistant-tb-in-heart-and-lungs 2025-10-28T09:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/kemwell-biopharma-s-bengaluru-facility-receives-fda-approval-for-commercial-biologics-manufacturing 2025-10-28T09:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kemwell-biopharma-s-bengaluru-facility-receives-fda-approval-for-commercial-biologics-manufacturing 2025-10-28T09:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-expands-bengaluru-r-d-center-with-160-crore-investment-to-advance-antibody-research 2025-10-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-expands-bengaluru-r-d-center-with-160-crore-investment-to-advance-antibody-research 2025-10-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/elixir-medical-s-dynamx-bioadaptor-achieves-48-reduction-in-coronary-events-in-landmark-trial 2025-10-28T05:29:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elixir-medical-s-dynamx-bioadaptor-achieves-48-reduction-in-coronary-events-in-landmark-trial 2025-10-28T05:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/myrio-therapeutics-forms-tri-party-alliance-with-penn-and-nyu-to-develop-next-generation-car-t-therapies-for-solid-tumors 2025-10-28T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myrio-therapeutics-forms-tri-party-alliance-with-penn-and-nyu-to-develop-next-generation-car-t-therapies-for-solid-tumors 2025-10-28T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-ic7fc-shows-dual-promise-against-type-2-diabetes-and-heart-disease 2025-10-28T05:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-ic7fc-shows-dual-promise-against-type-2-diabetes-and-heart-disease 2025-10-28T05:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/onward-therapeutics-secures-worldwide-license-for-novel-onco-metabolism-program-ot-s00x 2025-10-28T05:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onward-therapeutics-secures-worldwide-license-for-novel-onco-metabolism-program-ot-s00x 2025-10-28T05:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/egfr-mutated-nsclc-pipeline-expands-with-30-therapies-as-fda-approves-dato-dxd-and-j-j-combination-shows-survival-benefit 2025-10-28T05:25:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egfr-mutated-nsclc-pipeline-expands-with-30-therapies-as-fda-approves-dato-dxd-and-j-j-combination-shows-survival-benefit 2025-10-28T05:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/mit-study-shows-40hz-light-and-sound-therapy-slows-cognitive-decline-in-late-onset-alzheimer-s-disease 2025-10-28T01:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-study-shows-40hz-light-and-sound-therapy-slows-cognitive-decline-in-late-onset-alzheimer-s-disease 2025-10-28T01:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/fate-therapeutics-advances-two-phase-1-car-t-cell-therapy-studies-for-advanced-solid-tumors 2025-10-28T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fate-therapeutics-advances-two-phase-1-car-t-cell-therapy-studies-for-advanced-solid-tumors 2025-10-28T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-and-bon-secours-lead-evangeline-trial-testing-z-endoxifen-for-premenopausal-breast-cancer 2025-10-28T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-and-bon-secours-lead-evangeline-trial-testing-z-endoxifen-for-premenopausal-breast-cancer 2025-10-28T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-to-divest-roctavian-gene-therapy-following-commercial-struggles 2025-10-28T01:19:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-to-divest-roctavian-gene-therapy-following-commercial-struggles 2025-10-28T01:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-simplified-single-injection-maintenance-regimen-for-lilly-s-omvoh-in-ulcerative-colitis 2025-10-28T01:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-simplified-single-injection-maintenance-regimen-for-lilly-s-omvoh-in-ulcerative-colitis 2025-10-28T01:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-final-guidance-on-patient-focused-clinical-outcome-assessments-for-drug-development 2025-10-28T01:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-final-guidance-on-patient-focused-clinical-outcome-assessments-for-drug-development 2025-10-28T01:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-exercises-2-2-billion-option-on-prothena-s-tau-targeting-alzheimer-s-antibody 2025-10-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-exercises-2-2-billion-option-on-prothena-s-tau-targeting-alzheimer-s-antibody 2025-10-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/robert-packard-center-and-als-united-launch-joint-research-initiative-to-target-tdp-43-pathways-in-als 2025-10-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robert-packard-center-and-als-united-launch-joint-research-initiative-to-target-tdp-43-pathways-in-als 2025-10-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/life-btk-trial-shows-durable-3-year-benefits-of-dissolving-scaffold-in-below-the-knee-clti 2025-10-27T23:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-btk-trial-shows-durable-3-year-benefits-of-dissolving-scaffold-in-below-the-knee-clti 2025-10-27T23:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-launches-brekiya-first-self-administered-dhe-autoinjector-for-migraine-and-cluster-headaches 2025-10-27T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-launches-brekiya-first-self-administered-dhe-autoinjector-for-migraine-and-cluster-headaches 2025-10-27T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-to-present-first-clinical-data-from-dual-allogeneic-car-t-programs-in-lymphoma-and-multiple-myeloma 2025-10-27T21:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-to-present-first-clinical-data-from-dual-allogeneic-car-t-programs-in-lymphoma-and-multiple-myeloma 2025-10-27T21:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/adaptam-therapeutics-secures-eur3-million-to-develop-novel-cancer-immunotherapies-targeting-tumor-associated-myeloid-cells 2025-10-27T21:24:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptam-therapeutics-secures-eur3-million-to-develop-novel-cancer-immunotherapies-targeting-tumor-associated-myeloid-cells 2025-10-27T21:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-drive-2-7-billion-adc-investment-wave-in-2025 2025-10-27T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-companies-drive-2-7-billion-adc-investment-wave-in-2025 2025-10-27T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/sylamorebio-secures-3-million-nih-grant-to-develop-blood-brain-barrier-therapy-for-rare-neurodegenerative-disease 2025-10-27T21:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sylamorebio-secures-3-million-nih-grant-to-develop-blood-brain-barrier-therapy-for-rare-neurodegenerative-disease 2025-10-27T21:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-trials-15-minute-blood-test-to-rapidly-diagnose-sepsis-and-meningitis-in-children 2025-10-27T21:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-trials-15-minute-blood-test-to-rapidly-diagnose-sepsis-and-meningitis-in-children 2025-10-27T21:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/partner-3-trial-shows-tavr-maintains-equivalent-outcomes-to-surgery-at-7-years-in-low-risk-patients 2025-10-27T21:20:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/partner-3-trial-shows-tavr-maintains-equivalent-outcomes-to-surgery-at-7-years-in-low-risk-patients 2025-10-27T21:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/west-pharmaceutical-launches-synchrony-prefillable-syringe-system-to-streamline-biologics-delivery 2025-10-27T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-pharmaceutical-launches-synchrony-prefillable-syringe-system-to-streamline-biologics-delivery 2025-10-27T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/oric-pharmaceuticals-completes-dose-exploration-for-oric-944-in-prostate-cancer-shows-promising-efficacy-signals 2025-10-27T18:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-pharmaceuticals-completes-dose-exploration-for-oric-944-in-prostate-cancer-shows-promising-efficacy-signals 2025-10-27T18:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/bempedoic-acid-monotherapy-reduces-cardiovascular-events-by-14-and-venous-thromboembolism-by-42-in-clear-outcomes-analysis 2025-10-27T18:30:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bempedoic-acid-monotherapy-reduces-cardiovascular-events-by-14-and-venous-thromboembolism-by-42-in-clear-outcomes-analysis 2025-10-27T18:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/orchestra-biomed-initiates-pivotal-trial-for-novel-sirolimus-eluting-balloon-in-coronary-in-stent-restenosis 2025-10-27T18:28:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchestra-biomed-initiates-pivotal-trial-for-novel-sirolimus-eluting-balloon-in-coronary-in-stent-restenosis 2025-10-27T18:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-partners-with-enable-injections-to-develop-subcutaneous-delivery-system-for-first-in-class-mutcalr-therapy 2025-10-27T18:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-partners-with-enable-injections-to-develop-subcutaneous-delivery-system-for-first-in-class-mutcalr-therapy 2025-10-27T18:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/yorlabs-receives-fda-510-k-clearance-for-zero-capex-intracardiac-imaging-system 2025-10-27T18:25:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yorlabs-receives-fda-510-k-clearance-for-zero-capex-intracardiac-imaging-system 2025-10-27T18:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-s-jskn003-receives-fda-fast-track-designation-for-platinum-resistant-ovarian-cancer 2025-10-27T18:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphamab-oncology-s-jskn003-receives-fda-fast-track-designation-for-platinum-resistant-ovarian-cancer 2025-10-27T18:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/alphyn-secures-key-u-s-patent-for-atopic-dermatitis-drug-candidate-extending-ip-protection-to-2041 2025-10-27T18:25:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphyn-secures-key-u-s-patent-for-atopic-dermatitis-drug-candidate-extending-ip-protection-to-2041 2025-10-27T18:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/wellgistics-health-partners-with-datavault-ai-to-develop-blockchain-enabled-pharmacychain-technology-for-639-billion-prescription-drug-market 2025-10-27T18:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellgistics-health-partners-with-datavault-ai-to-develop-blockchain-enabled-pharmacychain-technology-for-639-billion-prescription-drug-market 2025-10-27T18:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapies-from-cabaletta-bio-and-bristol-myers-squibb-achieve-complete-remissions-in-severe-inflammatory-muscle-disease 2025-10-27T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-therapies-from-cabaletta-bio-and-bristol-myers-squibb-achieve-complete-remissions-in-severe-inflammatory-muscle-disease 2025-10-27T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-s-doc1021-shows-promising-survival-signal-in-phase-1-pancreatic-cancer-trial 2025-10-27T18:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diakonos-oncology-s-doc1021-shows-promising-survival-signal-in-phase-1-pancreatic-cancer-trial 2025-10-27T18:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-initiates-phase-1-trial-for-second-m4-muscarinic-receptor-modulator-nmra-898 2025-10-27T18:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-therapeutics-initiates-phase-1-trial-for-second-m4-muscarinic-receptor-modulator-nmra-898 2025-10-27T18:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-life-sciences-secures-31-million-through-warrant-exercise-to-advance-cancer-therapeutics-pipeline 2025-10-27T18:22:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-life-sciences-secures-31-million-through-warrant-exercise-to-advance-cancer-therapeutics-pipeline 2025-10-27T18:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/tolerance-bio-s-ipsc-derived-thymic-organoids-demonstrate-tumor-growth-inhibition-in-melanoma-model 2025-10-27T18:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tolerance-bio-s-ipsc-derived-thymic-organoids-demonstrate-tumor-growth-inhibition-in-melanoma-model 2025-10-27T18:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/chromatin-bioscience-partners-with-purespring-therapeutics-to-develop-precision-gene-therapy-promoters-for-kidney-disease 2025-10-27T18:21:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chromatin-bioscience-partners-with-purespring-therapeutics-to-develop-precision-gene-therapy-promoters-for-kidney-disease 2025-10-27T18:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-reports-sustained-efficacy-of-sotyktu-in-psoriatic-arthritis-and-lupus-through-extended-follow-up 2025-10-27T18:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-reports-sustained-efficacy-of-sotyktu-in-psoriatic-arthritis-and-lupus-through-extended-follow-up 2025-10-27T18:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/bahrain-partners-with-sandboxaq-in-1-billion-ai-driven-drug-discovery-initiative 2025-10-27T18:19:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bahrain-partners-with-sandboxaq-in-1-billion-ai-driven-drug-discovery-initiative 2025-10-27T18:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/graymatter-robotics-secures-afwerx-contract-to-develop-ai-powered-robotic-system-for-aerospace-optical-component-manufacturing 2025-10-27T18:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graymatter-robotics-secures-afwerx-contract-to-develop-ai-powered-robotic-system-for-aerospace-optical-component-manufacturing 2025-10-27T18:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/zenith-epigenetics-zen-3694-receives-fda-orphan-drug-designation-for-nut-carcinoma-treatment 2025-10-27T18:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenith-epigenetics-zen-3694-receives-fda-orphan-drug-designation-for-nut-carcinoma-treatment 2025-10-27T18:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-partners-with-zephyr-ai-to-advance-cancer-biomarker-discovery-through-ai-driven-precision-medicine 2025-10-27T18:17:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-partners-with-zephyr-ai-to-advance-cancer-biomarker-discovery-through-ai-driven-precision-medicine 2025-10-27T18:17:22+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-therapeutics-halts-phase-3-crispr-trials-after-patient-hospitalization-with-severe-liver-injury 2025-10-27T18:15:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellia-therapeutics-halts-phase-3-crispr-trials-after-patient-hospitalization-with-severe-liver-injury 2025-10-27T18:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/medera-advances-srd-001-gene-therapy-to-phase-2-trial-for-heart-failure-with-reduced-ejection-fraction 2025-10-27T13:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-advances-srd-001-gene-therapy-to-phase-2-trial-for-heart-failure-with-reduced-ejection-fraction 2025-10-27T13:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-therapies-secures-japanese-patent-for-thermostem-r-cell-based-obesity-treatment-platform 2025-10-27T13:25:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biorestorative-therapies-secures-japanese-patent-for-thermostem-r-cell-based-obesity-treatment-platform 2025-10-27T13:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/cohance-lifesciences-receives-oai-classification-from-fda-following-gmp-inspection-at-hyderabad-facility 2025-10-27T13:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cohance-lifesciences-receives-oai-classification-from-fda-following-gmp-inspection-at-hyderabad-facility 2025-10-27T13:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-s-first-in-class-ipf-drug-bersiporocin-clears-third-safety-review-phase-2-trial-nears-completion 2025-10-27T13:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-s-first-in-class-ipf-drug-bersiporocin-clears-third-safety-review-phase-2-trial-nears-completion 2025-10-27T13:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-s-obexelimab-achieves-95-reduction-in-brain-lesions-in-phase-2-multiple-sclerosis-trial 2025-10-27T13:20:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-s-obexelimab-achieves-95-reduction-in-brain-lesions-in-phase-2-multiple-sclerosis-trial 2025-10-27T13:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-completes-acquisition-of-japan-tobacco-s-pharmaceutical-business-and-plans-manufacturing-subsidiary-merger 2025-10-27T13:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-completes-acquisition-of-japan-tobacco-s-pharmaceutical-business-and-plans-manufacturing-subsidiary-merger 2025-10-27T13:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/cellcolabs-raises-12m-to-scale-mesenchymal-stem-cell-production-and-reduce-costs-by-90 2025-10-27T13:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellcolabs-raises-12m-to-scale-mesenchymal-stem-cell-production-and-reduce-costs-by-90 2025-10-27T13:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/nanoform-and-revio-therapeutics-partner-to-develop-gliora-a-novel-hydrogel-nanoformulation-for-high-grade-glioma-treatment 2025-10-27T13:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoform-and-revio-therapeutics-partner-to-develop-gliora-a-novel-hydrogel-nanoformulation-for-high-grade-glioma-treatment 2025-10-27T13:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-receives-25m-milestone-payment-from-bristol-myers-squibb-for-neuroscience-partnership-progress 2025-10-27T13:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-receives-25m-milestone-payment-from-bristol-myers-squibb-for-neuroscience-partnership-progress 2025-10-27T13:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-reports-positive-phase-3-results-for-bbp-418-in-rare-muscular-dystrophy 2025-10-27T13:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-reports-positive-phase-3-results-for-bbp-418-in-rare-muscular-dystrophy 2025-10-27T13:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/hemab-therapeutics-secures-157-million-series-c-to-advance-first-in-class-treatments-for-rare-bleeding-disorders 2025-10-27T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemab-therapeutics-secures-157-million-series-c-to-advance-first-in-class-treatments-for-rare-bleeding-disorders 2025-10-27T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-seeks-fda-meeting-for-paxalisib-conditional-approval-in-glioblastoma-under-project-frontrunner-initiative 2025-10-27T13:16:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-seeks-fda-meeting-for-paxalisib-conditional-approval-in-glioblastoma-under-project-frontrunner-initiative 2025-10-27T13:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/stempeutics-licenses-stem-cell-therapy-stempeucel-to-japanese-partner-for-critical-limb-threatening-ischemia-treatment 2025-10-27T13:16:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stempeutics-licenses-stem-cell-therapy-stempeucel-to-japanese-partner-for-critical-limb-threatening-ischemia-treatment 2025-10-27T13:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-acquires-exclusive-rights-to-syndivia-s-preclinical-adc-for-metastatic-castration-resistant-prostate-cancer 2025-10-27T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-acquires-exclusive-rights-to-syndivia-s-preclinical-adc-for-metastatic-castration-resistant-prostate-cancer 2025-10-27T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/4basebio-s-synthetic-dna-platform-advances-to-phase-i-ii-clinical-trials-with-global-pharma-partner 2025-10-27T09:19:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4basebio-s-synthetic-dna-platform-advances-to-phase-i-ii-clinical-trials-with-global-pharma-partner 2025-10-27T09:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/raffles-medical-group-partners-with-gene-solutions-to-streamline-cancer-clinical-trial-access-in-southeast-asia 2025-10-27T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raffles-medical-group-partners-with-gene-solutions-to-streamline-cancer-clinical-trial-access-in-southeast-asia 2025-10-27T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/adaptyx-biosciences-secures-14m-to-advance-multi-analyte-wearable-platform-for-continuous-molecular-monitoring 2025-10-27T05:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptyx-biosciences-secures-14m-to-advance-multi-analyte-wearable-platform-for-continuous-molecular-monitoring 2025-10-27T05:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-announces-12-billion-acquisition-of-avidity-biosciences-to-advance-rna-based-neuromuscular-therapeutics 2025-10-27T05:17:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-announces-12-billion-acquisition-of-avidity-biosciences-to-advance-rna-based-neuromuscular-therapeutics 2025-10-27T05:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/xencor-reports-initial-phase-1-results-for-xmab819-enpp3-x-cd3-bispecific-in-clear-cell-renal-cell-carcinoma 2025-10-27T01:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xencor-reports-initial-phase-1-results-for-xmab819-enpp3-x-cd3-bispecific-in-clear-cell-renal-cell-carcinoma 2025-10-27T01:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-confirms-safety-and-efficacy-of-transcatheter-tricuspid-valve-interventions 2025-10-27T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-confirms-safety-and-efficacy-of-transcatheter-tricuspid-valve-interventions 2025-10-27T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-symplicity-renal-denervation-shows-sustained-18-mmhg-blood-pressure-reduction-at-three-years 2025-10-27T01:15:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-symplicity-renal-denervation-shows-sustained-18-mmhg-blood-pressure-reduction-at-three-years 2025-10-27T01:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-test-shows-superior-early-lung-cancer-detection-compared-to-standard-ct-screening 2025-10-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-test-shows-superior-early-lung-cancer-detection-compared-to-standard-ct-screening 2025-10-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-biosciences-shares-surge-102-following-positive-phase-2-chondragon-trial-results-for-ozekibart-in-advanced-chondrosarcoma 2025-10-26T21:18:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-biosciences-shares-surge-102-following-positive-phase-2-chondragon-trial-results-for-ozekibart-in-advanced-chondrosarcoma 2025-10-26T21:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/cristcot-s-novel-ulcerative-colitis-suppository-achieves-rapid-clinical-remission-in-phase-3-trial 2025-10-26T21:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cristcot-s-novel-ulcerative-colitis-suppository-achieves-rapid-clinical-remission-in-phase-3-trial 2025-10-26T21:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-pursues-12-billion-acquisition-of-avidity-biosciences 2025-10-26T21:16:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-pursues-12-billion-acquisition-of-avidity-biosciences 2025-10-26T21:16:46+00:00 hourly 0.9 https://trial.medpath.com/news/phathom-pharmaceuticals-reports-positive-phase-3-results-for-voquezna-in-nocturnal-gerd-treatment 2025-10-26T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phathom-pharmaceuticals-reports-positive-phase-3-results-for-voquezna-in-nocturnal-gerd-treatment 2025-10-26T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/glaukos-receives-fda-approval-for-epioxa-keratoconus-treatment-stock-surges-13-5 2025-10-26T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glaukos-receives-fda-approval-for-epioxa-keratoconus-treatment-stock-surges-13-5 2025-10-26T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/ai-assisted-immune-profiling-reveals-novel-lymphocyte-signatures-in-soft-tissue-sarcoma 2025-10-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-assisted-immune-profiling-reveals-novel-lymphocyte-signatures-in-soft-tissue-sarcoma 2025-10-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/five-major-fda-decisions-expected-in-november-2025-across-cancer-rare-disease-and-genetic-disorders 2025-10-26T09:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-major-fda-decisions-expected-in-november-2025-across-cancer-rare-disease-and-genetic-disorders 2025-10-26T09:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/amprologix-advances-first-in-class-antibiotic-epidermicin-ni01-toward-human-trials 2025-10-26T01:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amprologix-advances-first-in-class-antibiotic-epidermicin-ni01-toward-human-trials 2025-10-26T01:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/x4-pharmaceuticals-secures-135-million-to-advance-mavorixafor-phase-3-trials 2025-10-26T01:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x4-pharmaceuticals-secures-135-million-to-advance-mavorixafor-phase-3-trials 2025-10-26T01:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/oric-pharmaceuticals-advances-cancer-drug-pipeline-with-promising-prostate-cancer-data-and-major-pharma-partnerships 2025-10-25T21:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-pharmaceuticals-advances-cancer-drug-pipeline-with-promising-prostate-cancer-data-and-major-pharma-partnerships 2025-10-25T21:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/voquezna-shows-rapid-relief-of-nighttime-gerd-symptoms-in-phase-3-trial 2025-10-25T21:16:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voquezna-shows-rapid-relief-of-nighttime-gerd-symptoms-in-phase-3-trial 2025-10-25T21:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/valthos-secures-30-million-to-develop-ai-powered-biodefense-platform-against-biological-threats 2025-10-25T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valthos-secures-30-million-to-develop-ai-powered-biodefense-platform-against-biological-threats 2025-10-25T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-establishes-sixth-global-r-d-center-in-beijing-to-accelerate-ai-driven-drug-discovery 2025-10-25T17:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-establishes-sixth-global-r-d-center-in-beijing-to-accelerate-ai-driven-drug-discovery 2025-10-25T17:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-reports-promising-car-t-cell-therapy-results-for-three-autoimmune-diseases 2025-10-25T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-reports-promising-car-t-cell-therapy-results-for-three-autoimmune-diseases 2025-10-25T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/quell-therapeutics-presents-promising-preclinical-data-for-qel-005-car-treg-therapy-at-acr-convergence-2025 2025-10-25T17:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quell-therapeutics-presents-promising-preclinical-data-for-qel-005-car-treg-therapy-at-acr-convergence-2025 2025-10-25T17:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/resmetirom-maintains-mash-efficacy-regardless-of-concurrent-diabetes-therapy-weight-loss-enhances-response 2025-10-25T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resmetirom-maintains-mash-efficacy-regardless-of-concurrent-diabetes-therapy-weight-loss-enhances-response 2025-10-25T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-advances-iga-nephropathy-treatment-with-positive-phase-3-origin-trial-results-and-fda-submission 2025-10-25T17:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-advances-iga-nephropathy-treatment-with-positive-phase-3-origin-trial-results-and-fda-submission 2025-10-25T17:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-therapeutics-advances-bnc-210-phase-3-trial-for-social-anxiety-disorder 2025-10-25T13:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuphoria-therapeutics-advances-bnc-210-phase-3-trial-for-social-anxiety-disorder 2025-10-25T13:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/cardiovalve-submits-ce-mark-application-for-transcatheter-tricuspid-valve-replacement-system-following-successful-target-study 2025-10-25T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiovalve-submits-ce-mark-application-for-transcatheter-tricuspid-valve-replacement-system-following-successful-target-study 2025-10-25T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-emergency-use-authorization-for-lotilaner-to-treat-new-world-screwworm-in-dogs 2025-10-25T05:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-emergency-use-authorization-for-lotilaner-to-treat-new-world-screwworm-in-dogs 2025-10-25T05:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-adverse-events-associated-with-fenofibric-acid-for-hyperlipidemia-treatment 2025-10-25T01:18:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-new-adverse-events-associated-with-fenofibric-acid-for-hyperlipidemia-treatment 2025-10-25T01:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-stock-surges-284-following-strategic-collaboration-with-anemocyte-for-gene-therapy-manufacturing 2025-10-25T01:17:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-science-stock-surges-284-following-strategic-collaboration-with-anemocyte-for-gene-therapy-manufacturing 2025-10-25T01:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/nipocalimab-demonstrates-significant-efficacy-in-phase-2-sjogren-s-disease-trial-published-in-the-lancet 2025-10-25T01:16:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nipocalimab-demonstrates-significant-efficacy-in-phase-2-sjogren-s-disease-trial-published-in-the-lancet 2025-10-25T01:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/whitehawk-therapeutics-validates-ptk7-as-third-most-abundant-adc-target-across-157000-tumor-samples 2025-10-24T21:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whitehawk-therapeutics-validates-ptk7-as-third-most-abundant-adc-target-across-157000-tumor-samples 2025-10-24T21:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/cogent-biosciences-unveils-promising-kras-inhibitor-data-with-superior-efficacy-profile 2025-10-24T21:21:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cogent-biosciences-unveils-promising-kras-inhibitor-data-with-superior-efficacy-profile 2025-10-24T21:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-javadin-oral-solution-for-hypertension-addressing-swallowing-difficulties-in-patient-care 2025-10-24T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-javadin-oral-solution-for-hypertension-addressing-swallowing-difficulties-in-patient-care 2025-10-24T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/omadacycline-shows-promise-in-phase-ii-trial-for-nontuberculous-mycobacterial-pulmonary-disease 2025-10-24T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omadacycline-shows-promise-in-phase-ii-trial-for-nontuberculous-mycobacterial-pulmonary-disease 2025-10-24T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-exclusive-rights-to-vanqua-bio-s-c5ar1-antagonist-for-inflammatory-diseases-in-1-06-billion-deal 2025-10-24T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-acquires-exclusive-rights-to-vanqua-bio-s-c5ar1-antagonist-for-inflammatory-diseases-in-1-06-billion-deal 2025-10-24T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/irish-consortium-secures-eur2-million-to-reduce-gene-therapy-manufacturing-costs 2025-10-24T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irish-consortium-secures-eur2-million-to-reduce-gene-therapy-manufacturing-costs 2025-10-24T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-and-anemocyte-expand-partnership-to-commercialize-lentiviral-vector-plasmid-dna-technology-platform 2025-10-24T17:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-science-and-anemocyte-expand-partnership-to-commercialize-lentiviral-vector-plasmid-dna-technology-platform 2025-10-24T17:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-acquires-adverum-biotechnologies-for-262m-to-advance-gene-therapy-for-wet-amd 2025-10-24T17:19:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-acquires-adverum-biotechnologies-for-262m-to-advance-gene-therapy-for-wet-amd 2025-10-24T17:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-banks-on-semaglutide-denosumab-and-abatacept-to-counter-revlimid-revenue-decline 2025-10-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-banks-on-semaglutide-denosumab-and-abatacept-to-counter-revlimid-revenue-decline 2025-10-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-global-rights-to-vanqua-bio-s-inflammatory-disorder-drug-in-1-06-billion-deal 2025-10-24T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-acquires-global-rights-to-vanqua-bio-s-inflammatory-disorder-drug-in-1-06-billion-deal 2025-10-24T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/giant-biogene-receives-nmpa-approval-for-first-recombinant-type-i-collagen-injectable-device 2025-10-24T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/giant-biogene-receives-nmpa-approval-for-first-recombinant-type-i-collagen-injectable-device 2025-10-24T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-phase-iii-success-triggers-850-stock-surge-reignites-european-biotech-rally 2025-10-24T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-phase-iii-success-triggers-850-stock-surge-reignites-european-biotech-rally 2025-10-24T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-biosciences-vtx3232-shows-78-reduction-in-key-inflammatory-marker-in-phase-ii-trial 2025-10-24T17:16:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventyx-biosciences-vtx3232-shows-78-reduction-in-key-inflammatory-marker-in-phase-ii-trial 2025-10-24T17:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-publishes-first-in-class-tdp-43-pet-tracer-data-in-nature-communications-advances-to-phase-1-trial 2025-10-24T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-publishes-first-in-class-tdp-43-pet-tracer-data-in-nature-communications-advances-to-phase-1-trial 2025-10-24T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/ribo-receives-ema-orphan-drug-designation-for-sirna-therapeutic-rbd1016-targeting-hepatitis-d-virus 2025-10-24T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribo-receives-ema-orphan-drug-designation-for-sirna-therapeutic-rbd1016-targeting-hepatitis-d-virus 2025-10-24T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/journey-medical-s-emrosi-demonstrates-superior-efficacy-over-oracea-in-phase-3-rosacea-trials 2025-10-24T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/journey-medical-s-emrosi-demonstrates-superior-efficacy-over-oracea-in-phase-3-rosacea-trials 2025-10-24T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/neuraxis-receives-first-ever-fda-clearance-for-functional-dyspepsia-treatment-in-adults 2025-10-24T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuraxis-receives-first-ever-fda-clearance-for-functional-dyspepsia-treatment-in-adults 2025-10-24T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-acquires-renalys-pharma-for-98-million-to-expand-kidney-disease-portfolio 2025-10-24T17:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-acquires-renalys-pharma-for-98-million-to-expand-kidney-disease-portfolio 2025-10-24T17:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-pharmaceuticals-advances-pan-kras-inhibitor-jab-23e73-through-clinical-development 2025-10-24T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-pharmaceuticals-advances-pan-kras-inhibitor-jab-23e73-through-clinical-development 2025-10-24T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/abolis-biotechnologies-and-euroapi-partner-to-restore-european-corticosteroid-production-through-microbial-biotechnology 2025-10-24T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abolis-biotechnologies-and-euroapi-partner-to-restore-european-corticosteroid-production-through-microbial-biotechnology 2025-10-24T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-presents-new-clinical-data-for-rare-inflammatory-disease-treatments-at-acr-2025 2025-10-24T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-presents-new-clinical-data-for-rare-inflammatory-disease-treatments-at-acr-2025 2025-10-24T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/curasen-therapeutics-initiates-phase-iia-trial-for-neurogenic-orthostatic-hypotension-treatment 2025-10-24T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curasen-therapeutics-initiates-phase-iia-trial-for-neurogenic-orthostatic-hypotension-treatment 2025-10-24T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/cns-bridging-radiotherapy-shows-acceptable-safety-profile-prior-to-car-t-in-b-cell-lymphoma 2025-10-24T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-bridging-radiotherapy-shows-acceptable-safety-profile-prior-to-car-t-in-b-cell-lymphoma 2025-10-24T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/neurobis-phase-ii-trial-launches-to-evaluate-cannabis-based-medicine-for-neurodegenerative-diseases 2025-10-24T09:16:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurobis-phase-ii-trial-launches-to-evaluate-cannabis-based-medicine-for-neurodegenerative-diseases 2025-10-24T09:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/tlx250-cdx-shows-promise-in-triple-negative-breast-cancer-as-opalescence-trial-results-published 2025-10-24T05:20:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tlx250-cdx-shows-promise-in-triple-negative-breast-cancer-as-opalescence-trial-results-published 2025-10-24T05:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/patient-advocacy-groups-launch-generic-cystic-fibrosis-drug-through-buyers-club-model 2025-10-24T05:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-advocacy-groups-launch-generic-cystic-fibrosis-drug-through-buyers-club-model 2025-10-24T05:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/biodesix-expands-bio-rad-partnership-to-develop-advanced-esr1-mutation-testing-for-breast-cancer 2025-10-24T05:17:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodesix-expands-bio-rad-partnership-to-develop-advanced-esr1-mutation-testing-for-breast-cancer 2025-10-24T05:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-oncology-s-bbo-11818-shows-promise-as-broad-spectrum-kras-inhibitor-in-preclinical-studies 2025-10-24T01:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-oncology-s-bbo-11818-shows-promise-as-broad-spectrum-kras-inhibitor-in-preclinical-studies 2025-10-24T01:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-to-sydnexis-for-syd-101-pediatric-myopia-treatment 2025-10-24T01:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-to-sydnexis-for-syd-101-pediatric-myopia-treatment 2025-10-24T01:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-s-shore-study-validates-allosure-heart-as-reliable-biomarker-for-heart-transplant-rejection 2025-10-24T01:19:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-s-shore-study-validates-allosure-heart-as-reliable-biomarker-for-heart-transplant-rejection 2025-10-24T01:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/pinetree-therapeutics-secures-47-million-series-b-to-advance-novel-protein-degraders-for-drug-resistant-cancers 2025-10-24T01:19:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pinetree-therapeutics-secures-47-million-series-b-to-advance-novel-protein-degraders-for-drug-resistant-cancers 2025-10-24T01:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-loqtorzi-as-first-immunotherapy-for-recurrent-nasopharyngeal-carcinoma 2025-10-24T01:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-loqtorzi-as-first-immunotherapy-for-recurrent-nasopharyngeal-carcinoma 2025-10-24T01:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-to-present-updated-mdna11-clinical-data-at-esmo-immuno-oncology-congress-2025 2025-10-24T01:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicenna-to-present-updated-mdna11-clinical-data-at-esmo-immuno-oncology-congress-2025 2025-10-24T01:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/medivir-licenses-hdac-inhibitor-remetinostat-to-biossil-for-global-cancer-development 2025-10-24T01:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medivir-licenses-hdac-inhibitor-remetinostat-to-biossil-for-global-cancer-development 2025-10-24T01:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/avava-receives-fda-clearance-for-wrinkle-treatment-using-focal-point-technology 2025-10-24T01:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avava-receives-fda-clearance-for-wrinkle-treatment-using-focal-point-technology 2025-10-24T01:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-releases-three-guidance-documents-to-streamline-drug-development-and-reduce-application-returns 2025-10-24T01:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-releases-three-guidance-documents-to-streamline-drug-development-and-reduce-application-returns 2025-10-24T01:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-s-opuswave-dual-sensor-imaging-system-receives-fda-510-k-clearance-for-coronary-artery-disease-treatment 2025-10-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-s-opuswave-dual-sensor-imaging-system-receives-fda-510-k-clearance-for-coronary-artery-disease-treatment 2025-10-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/svf-vaccines-reports-promising-preclinical-results-for-svf-001-immunotherapy-in-chronic-hepatitis-b-and-d-coinfection 2025-10-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/svf-vaccines-reports-promising-preclinical-results-for-svf-001-immunotherapy-in-chronic-hepatitis-b-and-d-coinfection 2025-10-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/queen-mary-university-launches-procyon-diagnostics-to-commercialize-revolutionary-pancreatic-cancer-early-detection-test 2025-10-23T21:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queen-mary-university-launches-procyon-diagnostics-to-commercialize-revolutionary-pancreatic-cancer-early-detection-test 2025-10-23T21:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/cerezentm-receives-european-approval-for-alzheimer-s-treatment-while-u-s-approval-remains-pending 2025-10-23T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerezentm-receives-european-approval-for-alzheimer-s-treatment-while-u-s-approval-remains-pending 2025-10-23T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-launches-oeb-5-gmp-bioconjugation-suite-to-accelerate-adc-development 2025-10-23T21:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syngene-international-launches-oeb-5-gmp-bioconjugation-suite-to-accelerate-adc-development 2025-10-23T21:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/vidac-pharma-to-explore-potential-collaboration-with-johnson-johnson-in-intratumoral-oncology 2025-10-23T21:23:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vidac-pharma-to-explore-potential-collaboration-with-johnson-johnson-in-intratumoral-oncology 2025-10-23T21:23:42+00:00 hourly 0.9 https://trial.medpath.com/news/pritelivir-shows-superior-efficacy-over-foscarnet-in-phase-ii-trial-for-resistant-hsv-infections 2025-10-23T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pritelivir-shows-superior-efficacy-over-foscarnet-in-phase-ii-trial-for-resistant-hsv-infections 2025-10-23T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/pleopharma-raises-36m-series-b-to-advance-first-in-class-cannabis-withdrawal-treatment-to-phase-3 2025-10-23T21:22:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pleopharma-raises-36m-series-b-to-advance-first-in-class-cannabis-withdrawal-treatment-to-phase-3 2025-10-23T21:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/major-leadership-transitions-reshape-pharmaceutical-industry-as-merck-kgaa-and-gsk-appoint-new-ceos 2025-10-23T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-leadership-transitions-reshape-pharmaceutical-industry-as-merck-kgaa-and-gsk-appoint-new-ceos 2025-10-23T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-presents-three-year-livdelzi-data-showing-liver-health-stabilization-in-primary-biliary-cholangitis-patients 2025-10-23T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-presents-three-year-livdelzi-data-showing-liver-health-stabilization-in-primary-biliary-cholangitis-patients 2025-10-23T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-novel-ultrasound-contrast-agent-asi-02-for-cardiac-imaging 2025-10-23T21:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-novel-ultrasound-contrast-agent-asi-02-for-cardiac-imaging 2025-10-23T21:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/clostrabio-launches-next-generation-probiotic-clb101-and-initiates-clinical-study-for-gut-health-applications 2025-10-23T21:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clostrabio-launches-next-generation-probiotic-clb101-and-initiates-clinical-study-for-gut-health-applications 2025-10-23T21:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/silence-therapeutics-completes-enrollment-in-phase-2-trial-of-first-in-class-sirna-for-polycythemia-vera 2025-10-23T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silence-therapeutics-completes-enrollment-in-phase-2-trial-of-first-in-class-sirna-for-polycythemia-vera 2025-10-23T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-biosciences-vtx3232-shows-80-reduction-in-cardiovascular-inflammation-markers-in-phase-2-trial 2025-10-23T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventyx-biosciences-vtx3232-shows-80-reduction-in-cardiovascular-inflammation-markers-in-phase-2-trial 2025-10-23T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-cipla-to-expand-tirzepatide-access-in-india-through-dual-brand-strategy 2025-10-23T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-partners-with-cipla-to-expand-tirzepatide-access-in-india-through-dual-brand-strategy 2025-10-23T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-hansoh-pharmaceutical-s-ret-inhibitor-application-for-lung-cancer-treatment 2025-10-23T17:27:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-accepts-hansoh-pharmaceutical-s-ret-inhibitor-application-for-lung-cancer-treatment 2025-10-23T17:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/oramed-advances-oral-insulin-program-with-new-u-s-trial-following-subgroup-analysis 2025-10-23T17:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oramed-advances-oral-insulin-program-with-new-u-s-trial-following-subgroup-analysis 2025-10-23T17:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/ginkgo-bioworks-partners-with-strm-bio-and-ubc-to-develop-in-vivo-car-therapies-for-autoimmune-diseases-under-arpa-h-program 2025-10-23T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ginkgo-bioworks-partners-with-strm-bio-and-ubc-to-develop-in-vivo-car-therapies-for-autoimmune-diseases-under-arpa-h-program 2025-10-23T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/phenix-trial-demonstrates-sentinel-lymph-node-biopsy-alone-is-noninferior-to-full-lymphadenectomy-in-early-stage-cervical-cancer 2025-10-23T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phenix-trial-demonstrates-sentinel-lymph-node-biopsy-alone-is-noninferior-to-full-lymphadenectomy-in-early-stage-cervical-cancer 2025-10-23T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/vial-initiates-phase-1-trial-of-novel-inhbe-sirna-therapy-for-obesity-treatment 2025-10-23T17:24:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vial-initiates-phase-1-trial-of-novel-inhbe-sirna-therapy-for-obesity-treatment 2025-10-23T17:24:29+00:00 hourly 0.9 https://trial.medpath.com/news/orion-secures-exclusive-license-for-abzena-s-cancer-targeting-monoclonal-antibody 2025-10-23T17:23:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-secures-exclusive-license-for-abzena-s-cancer-targeting-monoclonal-antibody 2025-10-23T17:23:18+00:00 hourly 0.9 https://trial.medpath.com/news/zeo-scientifix-poised-to-capitalize-on-florida-s-new-stem-cell-law-for-regenerative-medicine-market-expansion 2025-10-23T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeo-scientifix-poised-to-capitalize-on-florida-s-new-stem-cell-law-for-regenerative-medicine-market-expansion 2025-10-23T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-inc-completes-11m-asset-acquisition-of-ameluz-and-rhodoled-us-rights 2025-10-23T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-inc-completes-11m-asset-acquisition-of-ameluz-and-rhodoled-us-rights 2025-10-23T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-venture-funding-surges-70-9-in-q3-2025-signaling-market-recovery 2025-10-23T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-venture-funding-surges-70-9-in-q3-2025-signaling-market-recovery 2025-10-23T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/news/george-medicines-gmrx2-demonstrates-significant-reduction-in-recurrent-stroke-risk-for-ich-survivors-in-trident-trial 2025-10-23T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/george-medicines-gmrx2-demonstrates-significant-reduction-in-recurrent-stroke-risk-for-ich-survivors-in-trident-trial 2025-10-23T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/alloy-therapeutics-acquires-spannerwerks-to-expand-drug-development-capabilities 2025-10-23T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alloy-therapeutics-acquires-spannerwerks-to-expand-drug-development-capabilities 2025-10-23T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/protai-advances-ai-driven-drug-discovery-with-novel-tnfa-targeting-and-protein-degradation-technologies 2025-10-23T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protai-advances-ai-driven-drug-discovery-with-novel-tnfa-targeting-and-protein-degradation-technologies 2025-10-23T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/kure-cells-secures-10m-to-revolutionize-car-t-manufacturing-with-same-day-platform 2025-10-23T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kure-cells-secures-10m-to-revolutionize-car-t-manufacturing-with-same-day-platform 2025-10-23T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/vantage-hemp-co-initiates-european-regulatory-filings-for-pharmaceutical-grade-cbd 2025-10-23T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vantage-hemp-co-initiates-european-regulatory-filings-for-pharmaceutical-grade-cbd 2025-10-23T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/hebrew-university-researchers-develop-ribotac-technology-to-target-cancer-linked-terra-rna 2025-10-23T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hebrew-university-researchers-develop-ribotac-technology-to-target-cancer-linked-terra-rna 2025-10-23T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-s-hdp-101-adc-receives-fda-fast-track-designation-for-multiple-myeloma-treatment 2025-10-23T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-s-hdp-101-adc-receives-fda-fast-track-designation-for-multiple-myeloma-treatment 2025-10-23T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-initiates-phase-3-trial-of-safusidenib-for-high-grade-idh1-mutant-glioma-maintenance-treatment 2025-10-23T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-initiates-phase-3-trial-of-safusidenib-for-high-grade-idh1-mutant-glioma-maintenance-treatment 2025-10-23T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/new-drug-launch-prices-rise-51-despite-inflation-adjustments-icer-analysis-reveals 2025-10-23T17:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-drug-launch-prices-rise-51-despite-inflation-adjustments-icer-analysis-reveals 2025-10-23T17:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/roche-shares-drop-2-8-as-vabysmo-and-hemlibra-sales-miss-expectations-despite-revenue-growth 2025-10-23T13:22:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-shares-drop-2-8-as-vabysmo-and-hemlibra-sales-miss-expectations-despite-revenue-growth 2025-10-23T13:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-1345-rsv-vaccine-shows-safety-and-efficacy-in-solid-organ-transplant-recipients 2025-10-23T13:19:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-1345-rsv-vaccine-shows-safety-and-efficacy-in-solid-organ-transplant-recipients 2025-10-23T13:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-rarity-pbc-to-advance-first-commercial-gene-therapy-for-ada-scid-bubble-baby-disease 2025-10-23T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-partners-with-rarity-pbc-to-advance-first-commercial-gene-therapy-for-ada-scid-bubble-baby-disease 2025-10-23T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-and-eva-holding-group-partner-to-bring-first-ivd-certified-high-throughput-genetic-sequencer-to-brazil 2025-10-23T13:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgi-tech-and-eva-holding-group-partner-to-bring-first-ivd-certified-high-throughput-genetic-sequencer-to-brazil 2025-10-23T13:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/pazopanib-shows-promising-results-in-treating-children-with-multi-metastatic-ewing-sarcoma 2025-10-23T13:16:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pazopanib-shows-promising-results-in-treating-children-with-multi-metastatic-ewing-sarcoma 2025-10-23T13:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-to-launch-generic-ropivacaine-anesthesia-drug-in-us-market 2025-10-23T13:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-to-launch-generic-ropivacaine-anesthesia-drug-in-us-market 2025-10-23T13:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/thx-pharma-raises-eur8-million-to-advance-rare-neurological-disease-treatments 2025-10-23T09:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thx-pharma-raises-eur8-million-to-advance-rare-neurological-disease-treatments 2025-10-23T09:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-141984-bottles-of-generic-atorvastatin-due-to-failed-dissolution-standards 2025-10-23T09:16:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recalls-141984-bottles-of-generic-atorvastatin-due-to-failed-dissolution-standards 2025-10-23T09:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-receives-health-canada-approval-for-ustekinumab-biosimilar-yesintek 2025-10-23T09:16:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-receives-health-canada-approval-for-ustekinumab-biosimilar-yesintek 2025-10-23T09:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-expands-decade-long-partnership-with-medidata-to-accelerate-clinical-trial-development 2025-10-23T09:15:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-expands-decade-long-partnership-with-medidata-to-accelerate-clinical-trial-development 2025-10-23T09:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/accent-therapeutics-unveils-promising-preclinical-data-for-novel-cancer-therapies-atx-295-and-atx-559-at-major-oncology-conference 2025-10-23T05:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accent-therapeutics-unveils-promising-preclinical-data-for-novel-cancer-therapies-atx-295-and-atx-559-at-major-oncology-conference 2025-10-23T05:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-unveils-first-in-class-hmpl-a251-antibody-targeted-therapy-conjugate-with-superior-efficacy-against-her2-positive-cancers 2025-10-23T05:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-unveils-first-in-class-hmpl-a251-antibody-targeted-therapy-conjugate-with-superior-efficacy-against-her2-positive-cancers 2025-10-23T05:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-trial-demonstrates-safety-of-rectal-oxygen-delivery-for-respiratory-support 2025-10-23T05:15:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-trial-demonstrates-safety-of-rectal-oxygen-delivery-for-respiratory-support 2025-10-23T05:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/xcellon-biologics-expands-adc-development-capabilities-through-strategic-partnerships-with-invenra-and-intocell 2025-10-23T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xcellon-biologics-expands-adc-development-capabilities-through-strategic-partnerships-with-invenra-and-intocell 2025-10-23T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/gene-expression-test-reduces-need-for-invasive-lymph-node-biopsies-in-early-stage-melanoma-patients 2025-10-23T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-expression-test-reduces-need-for-invasive-lymph-node-biopsies-in-early-stage-melanoma-patients 2025-10-23T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/aptis-expands-adc-platform-through-strategic-partnerships-for-next-generation-cancer-therapeutics 2025-10-23T01:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptis-expands-adc-platform-through-strategic-partnerships-for-next-generation-cancer-therapeutics 2025-10-23T01:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-blocks-ingenus-from-pursuing-cancer-drug-patent-claims-after-prior-invalidation 2025-10-23T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-court-blocks-ingenus-from-pursuing-cancer-drug-patent-claims-after-prior-invalidation 2025-10-23T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-pazopanib-outperforms-sunitinib-in-advanced-alveolar-soft-part-sarcoma 2025-10-23T01:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-pazopanib-outperforms-sunitinib-in-advanced-alveolar-soft-part-sarcoma 2025-10-23T01:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-discontinues-cmv-vaccine-development-after-phase-3-trial-fails-to-meet-primary-endpoint 2025-10-23T01:17:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-discontinues-cmv-vaccine-development-after-phase-3-trial-fails-to-meet-primary-endpoint 2025-10-23T01:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-to-present-topline-results-from-registrational-chondrosarcoma-trial-of-ozekibart 2025-10-23T01:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-to-present-topline-results-from-registrational-chondrosarcoma-trial-of-ozekibart 2025-10-23T01:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/swallowable-bioluminescent-capsule-shows-promise-for-early-detection-of-life-threatening-intestinal-blood-flow-disorder 2025-10-22T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swallowable-bioluminescent-capsule-shows-promise-for-early-detection-of-life-threatening-intestinal-blood-flow-disorder 2025-10-22T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-and-jazz-pharmaceuticals-settle-90-million-narcolepsy-drug-dispute-over-lumryz 2025-10-22T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-and-jazz-pharmaceuticals-settle-90-million-narcolepsy-drug-dispute-over-lumryz 2025-10-22T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/cyncado-therapeutics-presents-first-evidence-of-a2b-receptor-inhibition-s-direct-anti-tumor-effects-in-mesothelioma 2025-10-22T21:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyncado-therapeutics-presents-first-evidence-of-a2b-receptor-inhibition-s-direct-anti-tumor-effects-in-mesothelioma 2025-10-22T21:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-inhaled-mrna-therapy-arct-032-shows-mixed-results-in-phase-2-cystic-fibrosis-trial 2025-10-22T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-inhaled-mrna-therapy-arct-032-shows-mixed-results-in-phase-2-cystic-fibrosis-trial 2025-10-22T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-louisville-receives-11-5-million-nih-grant-to-advance-cancer-immunotherapy-research-and-training 2025-10-22T21:19:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-louisville-receives-11-5-million-nih-grant-to-advance-cancer-immunotherapy-research-and-training 2025-10-22T21:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/basking-biosciences-advances-phase-2-stroke-trial-with-new-ceo-appointment-and-27-5m-funding 2025-10-22T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basking-biosciences-advances-phase-2-stroke-trial-with-new-ceo-appointment-and-27-5m-funding 2025-10-22T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/zenocutuzumab-shows-37-response-rate-in-rare-nrg1-positive-cholangiocarcinoma 2025-10-22T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenocutuzumab-shows-37-response-rate-in-rare-nrg1-positive-cholangiocarcinoma 2025-10-22T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/alkermes-acquires-avadel-for-up-to-2-1b-to-accelerate-sleep-medicine-market-entry 2025-10-22T21:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkermes-acquires-avadel-for-up-to-2-1b-to-accelerate-sleep-medicine-market-entry 2025-10-22T21:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/biokin-receives-record-250-million-adc-milestone-payment-from-bristol-myers-squibb 2025-10-22T21:16:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biokin-receives-record-250-million-adc-milestone-payment-from-bristol-myers-squibb 2025-10-22T21:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/gempharmatech-partners-with-memorial-sloan-kettering-to-accelerate-fully-human-antibody-discovery-for-cancer-therapy 2025-10-22T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gempharmatech-partners-with-memorial-sloan-kettering-to-accelerate-fully-human-antibody-discovery-for-cancer-therapy 2025-10-22T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/ensifentrine-demonstrates-sustained-improvement-in-copd-symptoms-and-quality-of-life-in-stable-patients 2025-10-22T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensifentrine-demonstrates-sustained-improvement-in-copd-symptoms-and-quality-of-life-in-stable-patients 2025-10-22T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-fcrn-inhibitor-prevents-congenital-heart-block-in-high-risk-pregnancy 2025-10-22T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-fcrn-inhibitor-prevents-congenital-heart-block-in-high-risk-pregnancy 2025-10-22T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-s-ai-designed-drug-mts-004-becomes-first-in-china-to-complete-phase-iii-trial-for-pseudobulbar-affect 2025-10-22T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-techbio-s-ai-designed-drug-mts-004-becomes-first-in-china-to-complete-phase-iii-trial-for-pseudobulbar-affect 2025-10-22T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/medherant-s-testosterone-patch-shows-promise-in-phase-1-trial-for-menopausal-women 2025-10-22T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medherant-s-testosterone-patch-shows-promise-in-phase-1-trial-for-menopausal-women 2025-10-22T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-r-d-pipeline-expands-to-over-300-drugs-with-novel-protacs-adcs-and-cdk-inhibitors 2025-10-22T17:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-r-d-pipeline-expands-to-over-300-drugs-with-novel-protacs-adcs-and-cdk-inhibitors 2025-10-22T17:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/addenbrooke-s-hospital-becomes-first-in-europe-to-deliver-histotripsy-cancer-treatment-outside-clinical-trials 2025-10-22T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addenbrooke-s-hospital-becomes-first-in-europe-to-deliver-histotripsy-cancer-treatment-outside-clinical-trials 2025-10-22T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/global-registry-data-confirms-survival-advantage-of-mogamulizumab-in-advanced-cutaneous-t-cell-lymphoma 2025-10-22T17:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-registry-data-confirms-survival-advantage-of-mogamulizumab-in-advanced-cutaneous-t-cell-lymphoma 2025-10-22T17:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/adarx-pharmaceuticals-initiates-phase-3-trial-for-adx-324-in-hereditary-angioedema-receives-fda-orphan-drug-designation 2025-10-22T17:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adarx-pharmaceuticals-initiates-phase-3-trial-for-adx-324-in-hereditary-angioedema-receives-fda-orphan-drug-designation 2025-10-22T17:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/sironax-strengthens-leadership-team-with-two-senior-appointments-to-advance-age-related-disease-pipeline 2025-10-22T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sironax-strengthens-leadership-team-with-two-senior-appointments-to-advance-age-related-disease-pipeline 2025-10-22T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/symrise-invests-in-cellibre-to-advance-precision-fermentation-technology-for-flavor-and-cosmetic-ingredients 2025-10-22T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symrise-invests-in-cellibre-to-advance-precision-fermentation-technology-for-flavor-and-cosmetic-ingredients 2025-10-22T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/electra-therapeutics-ela026-receives-fda-breakthrough-therapy-and-ema-priority-designations-for-rare-inflammatory-disease 2025-10-22T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electra-therapeutics-ela026-receives-fda-breakthrough-therapy-and-ema-priority-designations-for-rare-inflammatory-disease 2025-10-22T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/gammatile-reduces-brain-metastases-recurrence-risk-by-over-50-in-phase-3-roads-trial 2025-10-22T17:16:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gammatile-reduces-brain-metastases-recurrence-risk-by-over-50-in-phase-3-roads-trial 2025-10-22T17:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/solenic-medical-s-alternating-magnetic-field-technology-shows-promise-in-fda-authorized-compassionate-use-for-prosthetic-joint-infection 2025-10-22T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solenic-medical-s-alternating-magnetic-field-technology-shows-promise-in-fda-authorized-compassionate-use-for-prosthetic-joint-infection 2025-10-22T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/partitionbio-wins-elrig-innovation-award-for-peptide-based-cell-delivery-platform 2025-10-22T17:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/partitionbio-wins-elrig-innovation-award-for-peptide-based-cell-delivery-platform 2025-10-22T17:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-drug-under-new-priority-voucher-program-fast-tracking-augmentin-xr-to-strengthen-us-manufacturing 2025-10-22T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-drug-under-new-priority-voucher-program-fast-tracking-augmentin-xr-to-strengthen-us-manufacturing 2025-10-22T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-expands-prophetnsclc-r-precision-oncology-test-nationwide-with-new-york-state-laboratory-permit 2025-10-22T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncohost-expands-prophetnsclc-r-precision-oncology-test-nationwide-with-new-york-state-laboratory-permit 2025-10-22T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-launches-first-immunotherapy-program-for-colorectal-cancer-in-sub-saharan-africa 2025-10-22T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-launches-first-immunotherapy-program-for-colorectal-cancer-in-sub-saharan-africa 2025-10-22T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-pharmacovigilance-study-reveals-distinct-infection-risk-profiles-among-immune-checkpoint-inhibitors 2025-10-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-pharmacovigilance-study-reveals-distinct-infection-risk-profiles-among-immune-checkpoint-inhibitors 2025-10-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/private-equity-consortium-lowers-acceptance-threshold-for-bavarian-nordic-takeover-amid-shareholder-opposition 2025-10-22T13:24:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/private-equity-consortium-lowers-acceptance-threshold-for-bavarian-nordic-takeover-amid-shareholder-opposition 2025-10-22T13:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-initiates-first-in-human-study-of-intranasal-oxytocin-for-rare-endocrine-disorder 2025-10-22T13:22:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-initiates-first-in-human-study-of-intranasal-oxytocin-for-rare-endocrine-disorder 2025-10-22T13:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-urine-test-could-replace-invasive-kidney-biopsies-for-lupus-nephritis-monitoring 2025-10-22T13:18:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-urine-test-could-replace-invasive-kidney-biopsies-for-lupus-nephritis-monitoring 2025-10-22T13:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/smartbax-secures-eur4-7m-to-advance-novel-antibiotic-compounds-against-multi-drug-resistant-bacteria 2025-10-22T13:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartbax-secures-eur4-7m-to-advance-novel-antibiotic-compounds-against-multi-drug-resistant-bacteria 2025-10-22T13:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/elevara-medicines-secures-70-million-series-a-to-advance-novel-cdk4-6-inhibitor-for-rheumatoid-arthritis 2025-10-22T13:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevara-medicines-secures-70-million-series-a-to-advance-novel-cdk4-6-inhibitor-for-rheumatoid-arthritis 2025-10-22T13:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-launches-ps2m-ai-initiative-to-predict-drug-interactions-and-accelerate-medicine-approvals 2025-10-22T13:18:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-launches-ps2m-ai-initiative-to-predict-drug-interactions-and-accelerate-medicine-approvals 2025-10-22T13:18:21+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-restructures-leadership-team-with-new-commercial-operations-appointments 2025-10-22T13:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-restructures-leadership-team-with-new-commercial-operations-appointments 2025-10-22T13:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-launches-expedition-medicines-with-50m-investment-in-ai-driven-covalent-drug-discovery 2025-10-22T13:17:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-launches-expedition-medicines-with-50m-investment-in-ai-driven-covalent-drug-discovery 2025-10-22T13:17:02+00:00 hourly 0.9 https://trial.medpath.com/news/ena-respiratory-raises-22-4m-to-advance-inna-051-nasal-spray-in-phase-ii-trial-for-respiratory-virus-prevention 2025-10-22T13:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ena-respiratory-raises-22-4m-to-advance-inna-051-nasal-spray-in-phase-ii-trial-for-respiratory-virus-prevention 2025-10-22T13:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-next-generation-low-carbon-ventolin-inhaler-shows-therapeutic-equivalence-in-phase-iii-trial 2025-10-22T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-next-generation-low-carbon-ventolin-inhaler-shows-therapeutic-equivalence-in-phase-iii-trial 2025-10-22T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-cosentyx-achieves-primary-and-secondary-endpoints-in-phase-iii-polymyalgia-rheumatica-trial 2025-10-22T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-cosentyx-achieves-primary-and-secondary-endpoints-in-phase-iii-polymyalgia-rheumatica-trial 2025-10-22T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-efdoralprin-alfa-achieves-primary-endpoints-in-phase-2-alpha-1-antitrypsin-deficiency-study 2025-10-22T09:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-efdoralprin-alfa-achieves-primary-endpoints-in-phase-2-alpha-1-antitrypsin-deficiency-study 2025-10-22T09:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-acquires-imcheck-therapeutics-for-eur1-billion-to-advance-novel-aml-immunotherapy 2025-10-22T09:16:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-acquires-imcheck-therapeutics-for-eur1-billion-to-advance-novel-aml-immunotherapy 2025-10-22T09:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finds-egregious-manufacturing-violations-at-nephron-pharmaceuticals-despite-years-of-warnings 2025-10-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-finds-egregious-manufacturing-violations-at-nephron-pharmaceuticals-despite-years-of-warnings 2025-10-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/revium-rx-advances-nano-mupirocin-toward-phase-1-trials-to-combat-antibiotic-resistant-infections 2025-10-22T05:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revium-rx-advances-nano-mupirocin-toward-phase-1-trials-to-combat-antibiotic-resistant-infections 2025-10-22T05:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/india-proposes-regulatory-framework-for-cell-and-gene-therapy-manufacturing-licenses 2025-10-22T05:15:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-proposes-regulatory-framework-for-cell-and-gene-therapy-manufacturing-licenses 2025-10-22T05:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-and-innovent-biologics-form-11-4-billion-strategic-partnership-to-advance-next-generation-cancer-therapies 2025-10-22T05:15:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-and-innovent-biologics-form-11-4-billion-strategic-partnership-to-advance-next-generation-cancer-therapies 2025-10-22T05:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/early-oncology-data-becomes-critical-driver-of-investment-as-pharma-funding-contracts 2025-10-22T03:14:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-oncology-data-becomes-critical-driver-of-investment-as-pharma-funding-contracts 2025-10-22T03:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-s-dna-encoded-antibody-platform-achieves-72-week-sustained-expression-in-phase-1-trial 2025-10-22T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-s-dna-encoded-antibody-platform-achieves-72-week-sustained-expression-in-phase-1-trial 2025-10-22T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/shuttle-pharmaceuticals-signs-10m-loi-to-acquire-ai-platform-molecule-ai-to-enhance-radiation-therapy-development 2025-10-22T01:22:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shuttle-pharmaceuticals-signs-10m-loi-to-acquire-ai-platform-molecule-ai-to-enhance-radiation-therapy-development 2025-10-22T01:22:35+00:00 hourly 0.9 https://trial.medpath.com/news/chemify-secures-50-million-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-10-22T01:22:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemify-secures-50-million-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-10-22T01:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/selection-s-si-544-demonstrates-disease-modifying-potential-in-phase-1b-psoriasis-trial 2025-10-22T01:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selection-s-si-544-demonstrates-disease-modifying-potential-in-phase-1b-psoriasis-trial 2025-10-22T01:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/french-cultivated-meat-companies-gourmey-and-vital-meat-merge-to-form-parima-creating-global-leader-in-cell-based-animal-production 2025-10-22T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-cultivated-meat-companies-gourmey-and-vital-meat-merge-to-form-parima-creating-global-leader-in-cell-based-animal-production 2025-10-22T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/oracle-and-baylor-college-of-medicine-launch-major-ai-driven-research-initiative-to-combat-rising-alcohol-related-liver-disease 2025-10-22T01:16:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oracle-and-baylor-college-of-medicine-launch-major-ai-driven-research-initiative-to-combat-rising-alcohol-related-liver-disease 2025-10-22T01:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/alector-s-latozinemab-fails-phase-iii-trial-for-frontotemporal-dementia-company-cuts-workforce-by-half 2025-10-22T01:16:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alector-s-latozinemab-fails-phase-iii-trial-for-frontotemporal-dementia-company-cuts-workforce-by-half 2025-10-22T01:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/trivarx-completes-recruitment-for-60-patient-veterans-mental-health-trial-using-novel-ecg-algorithm 2025-10-22T01:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trivarx-completes-recruitment-for-60-patient-veterans-mental-health-trial-using-novel-ecg-algorithm 2025-10-22T01:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/pharmajet-expands-needle-free-technology-portfolio-with-self-injection-pen-development 2025-10-21T21:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmajet-expands-needle-free-technology-portfolio-with-self-injection-pen-development 2025-10-21T21:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/light-chain-bioscience-reports-promising-survival-data-for-ni-1801-bispecific-antibody-in-platinum-resistant-ovarian-cancer 2025-10-21T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-chain-bioscience-reports-promising-survival-data-for-ni-1801-bispecific-antibody-in-platinum-resistant-ovarian-cancer 2025-10-21T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-galway-researchers-discover-sugar-coating-mechanism-that-helps-bowel-cancer-evade-immune-system 2025-10-21T21:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-galway-researchers-discover-sugar-coating-mechanism-that-helps-bowel-cancer-evade-immune-system 2025-10-21T21:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-s-perioperative-immunotherapy-combo-achieves-breakthrough-in-hepatocellular-carcinoma-treatment 2025-10-21T21:20:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-s-perioperative-immunotherapy-combo-achieves-breakthrough-in-hepatocellular-carcinoma-treatment 2025-10-21T21:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/medibeacon-s-transdermal-gfr-system-receives-china-approval-opening-major-market-for-point-of-care-kidney-function-testing 2025-10-21T21:17:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medibeacon-s-transdermal-gfr-system-receives-china-approval-opening-major-market-for-point-of-care-kidney-function-testing 2025-10-21T21:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/dermatology-clinical-trials-evolve-to-meet-rising-efficacy-standards-and-biologic-innovation 2025-10-21T21:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dermatology-clinical-trials-evolve-to-meet-rising-efficacy-standards-and-biologic-innovation 2025-10-21T21:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/theraclion-s-sonovein-r-hifu-platform-achieves-key-chinese-safety-certification-advancing-toward-nmpa-market-authorization 2025-10-21T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theraclion-s-sonovein-r-hifu-platform-achieves-key-chinese-safety-certification-advancing-toward-nmpa-market-authorization 2025-10-21T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/indian-phase-iii-trial-shows-carboplatin-benefits-premenopausal-triple-negative-breast-cancer-patients 2025-10-21T21:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-phase-iii-trial-shows-carboplatin-benefits-premenopausal-triple-negative-breast-cancer-patients 2025-10-21T21:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/pranax-s-licensed-exosome-manufacturing-technology-demonstrates-safety-in-phase-i-pancreatic-cancer-trial 2025-10-21T21:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pranax-s-licensed-exosome-manufacturing-technology-demonstrates-safety-in-phase-i-pancreatic-cancer-trial 2025-10-21T21:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-s-precem-tct-adc-shows-31-response-rate-in-colorectal-cancer-advances-to-phase-iii 2025-10-21T21:16:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-s-precem-tct-adc-shows-31-response-rate-in-colorectal-cancer-advances-to-phase-iii 2025-10-21T21:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/bptf-protein-emerges-as-key-target-to-overcome-hormone-therapy-resistance-in-er-breast-cancer 2025-10-21T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bptf-protein-emerges-as-key-target-to-overcome-hormone-therapy-resistance-in-er-breast-cancer 2025-10-21T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/onkos-surgical-receives-fda-510-k-clearance-for-eleos-proximal-tibia-with-nanocept-antibacterial-technology 2025-10-21T21:16:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onkos-surgical-receives-fda-510-k-clearance-for-eleos-proximal-tibia-with-nanocept-antibacterial-technology 2025-10-21T21:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/curia-s-burlington-sterile-manufacturing-facility-wins-massachusetts-manufacturer-of-the-year-award 2025-10-21T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curia-s-burlington-sterile-manufacturing-facility-wins-massachusetts-manufacturer-of-the-year-award 2025-10-21T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-faces-generic-competition-as-two-companies-file-abbreviated-new-drug-applications-for-exparel 2025-10-21T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-faces-generic-competition-as-two-companies-file-abbreviated-new-drug-applications-for-exparel 2025-10-21T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-and-orphan-drug-designations-to-nbm-bmx-for-metastatic-uveal-melanoma 2025-10-21T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-and-orphan-drug-designations-to-nbm-bmx-for-metastatic-uveal-melanoma 2025-10-21T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-faces-generic-challenge-as-whiteoak-files-anda-for-exparel 2025-10-21T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-faces-generic-challenge-as-whiteoak-files-anda-for-exparel 2025-10-21T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/simcha-therapeutics-reports-enhanced-cancer-treatment-efficacy-with-decoy-resistant-il-18-and-bispecific-t-cell-engagers 2025-10-21T17:22:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcha-therapeutics-reports-enhanced-cancer-treatment-efficacy-with-decoy-resistant-il-18-and-bispecific-t-cell-engagers 2025-10-21T17:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-subcutaneous-pembrolizumab-for-solid-tumors-transforming-bladder-cancer-treatment-delivery 2025-10-21T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-pembrolizumab-for-solid-tumors-transforming-bladder-cancer-treatment-delivery 2025-10-21T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-partners-with-contera-pharma-to-develop-rna-targeting-oligonucleotide-therapies-for-neurological-disorders 2025-10-21T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-partners-with-contera-pharma-to-develop-rna-targeting-oligonucleotide-therapies-for-neurological-disorders 2025-10-21T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-buran-trial-shows-buparlisib-paclitaxel-combination-fails-to-improve-survival-in-pd-1-refractory-head-and-neck-cancer 2025-10-21T17:19:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-buran-trial-shows-buparlisib-paclitaxel-combination-fails-to-improve-survival-in-pd-1-refractory-head-and-neck-cancer 2025-10-21T17:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/gld-partners-acquires-seelos-therapeutics-assets-advancing-ketamine-and-trehalose-programs-to-phase-3-trials 2025-10-21T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gld-partners-acquires-seelos-therapeutics-assets-advancing-ketamine-and-trehalose-programs-to-phase-3-trials 2025-10-21T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/quoin-pharmaceuticals-receives-fda-orphan-drug-designation-for-qrx003-in-netherton-syndrome-treatment 2025-10-21T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-receives-fda-orphan-drug-designation-for-qrx003-in-netherton-syndrome-treatment 2025-10-21T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-asundexian-meets-primary-endpoints-in-phase-iii-oceanic-stroke-trial-for-secondary-stroke-prevention 2025-10-21T17:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-asundexian-meets-primary-endpoints-in-phase-iii-oceanic-stroke-trial-for-secondary-stroke-prevention 2025-10-21T17:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-shows-clinical-promise-but-faces-cost-effectiveness-hurdles-in-china-s-small-cell-lung-cancer-treatment 2025-10-21T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-shows-clinical-promise-but-faces-cost-effectiveness-hurdles-in-china-s-small-cell-lung-cancer-treatment 2025-10-21T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/ventus-therapeutics-partners-with-genentech-in-460m-ai-driven-drug-discovery-collaboration 2025-10-21T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventus-therapeutics-partners-with-genentech-in-460m-ai-driven-drug-discovery-collaboration 2025-10-21T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reports-death-in-patient-treated-with-ascendis-pharma-s-yorvipath-raising-safety-questions 2025-10-21T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reports-death-in-patient-treated-with-ascendis-pharma-s-yorvipath-raising-safety-questions 2025-10-21T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/tenon-medical-receives-fda-510-k-clearance-for-simmetry-si-joint-fusion-system 2025-10-21T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenon-medical-receives-fda-510-k-clearance-for-simmetry-si-joint-fusion-system 2025-10-21T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-s-gazyva-for-lupus-nephritis-treatment-expanding-therapeutic-options 2025-10-21T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-s-gazyva-for-lupus-nephritis-treatment-expanding-therapeutic-options 2025-10-21T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/caremetx-and-syneos-health-form-strategic-partnership-to-accelerate-specialty-medication-access 2025-10-21T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caremetx-and-syneos-health-form-strategic-partnership-to-accelerate-specialty-medication-access 2025-10-21T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/precision-immunomodulation-emerges-as-key-strategy-to-balance-inflammation-and-restore-tissue-homeostasis 2025-10-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-immunomodulation-emerges-as-key-strategy-to-balance-inflammation-and-restore-tissue-homeostasis 2025-10-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eleva-s-cpv-104-advances-to-phase-1b-testing-in-c3g-patients-after-successful-safety-evaluation 2025-10-21T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eleva-s-cpv-104-advances-to-phase-1b-testing-in-c3g-patients-after-successful-safety-evaluation 2025-10-21T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-to-present-preclinical-data-on-first-in-class-activin-e-antibody-ibio-610-for-obesity-treatment 2025-10-21T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-to-present-preclinical-data-on-first-in-class-activin-e-antibody-ibio-610-for-obesity-treatment 2025-10-21T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-enhanced-mortality-benefits-in-type-2-diabetes-patients-with-sleep-apnea 2025-10-21T13:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-show-enhanced-mortality-benefits-in-type-2-diabetes-patients-with-sleep-apnea 2025-10-21T13:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-epigenetic-editing-platform-enables-safe-multi-gene-modification-in-car-t-cells 2025-10-21T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-epigenetic-editing-platform-enables-safe-multi-gene-modification-in-car-t-cells 2025-10-21T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/vcn-01-oncolytic-virus-shows-promising-survival-benefits-in-metastatic-pancreatic-cancer-trial 2025-10-21T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcn-01-oncolytic-virus-shows-promising-survival-benefits-in-metastatic-pancreatic-cancer-trial 2025-10-21T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-receives-japanese-regulatory-approval-for-bcma-car-t-clinical-trial 2025-10-21T13:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iaso-bio-receives-japanese-regulatory-approval-for-bcma-car-t-clinical-trial 2025-10-21T13:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/bovine-tb-cattle-vaccine-field-trials-advance-to-phase-3-with-750-animals-across-uk-farms 2025-10-21T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bovine-tb-cattle-vaccine-field-trials-advance-to-phase-3-with-750-animals-across-uk-farms 2025-10-21T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-s-hcb101-shows-promising-safety-profile-and-early-efficacy-in-phase-1-cancer-trial 2025-10-21T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanchorbio-s-hcb101-shows-promising-safety-profile-and-early-efficacy-in-phase-1-cancer-trial 2025-10-21T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/gondolabio-s-port-77-receives-fda-orphan-drug-and-fast-track-designations-for-rare-protoporphyria-treatment 2025-10-21T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gondolabio-s-port-77-receives-fda-orphan-drug-and-fast-track-designations-for-rare-protoporphyria-treatment 2025-10-21T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/ferrer-completes-early-enrollment-for-phase-ii-psp-trial-testing-novel-oga-inhibitor-fnp-223 2025-10-21T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferrer-completes-early-enrollment-for-phase-ii-psp-trial-testing-novel-oga-inhibitor-fnp-223 2025-10-21T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/crisproff-epigenetic-editing-enables-durable-gene-silencing-in-car-t-cell-therapy 2025-10-21T13:21:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crisproff-epigenetic-editing-enables-durable-gene-silencing-in-car-t-cell-therapy 2025-10-21T13:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-partners-with-phrontline-to-develop-next-generation-dual-payload-adcs-for-cancer-treatment 2025-10-21T09:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-partners-with-phrontline-to-develop-next-generation-dual-payload-adcs-for-cancer-treatment 2025-10-21T09:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/europe-s-first-ranibizumab-biosimilar-pre-filled-syringe-launches-in-france 2025-10-21T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/europe-s-first-ranibizumab-biosimilar-pre-filled-syringe-launches-in-france 2025-10-21T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-and-eurofarma-launch-ai-powered-epilepsy-management-joint-venture 2025-10-21T09:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-and-eurofarma-launch-ai-powered-epilepsy-management-joint-venture 2025-10-21T09:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-presents-early-clinical-data-for-novel-oncology-therapies-at-esmo-congress-2025 2025-10-21T09:16:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-presents-early-clinical-data-for-novel-oncology-therapies-at-esmo-congress-2025 2025-10-21T09:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-70-response-rate-for-novel-combination-therapy-in-advanced-neuroendocrine-tumors 2025-10-21T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-70-response-rate-for-novel-combination-therapy-in-advanced-neuroendocrine-tumors 2025-10-21T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/solaria-bio-s-bondiatm-demonstrates-85-improvement-in-bone-density-through-novel-gut-bone-axis-targeting 2025-10-21T05:28:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solaria-bio-s-bondiatm-demonstrates-85-improvement-in-bone-density-through-novel-gut-bone-axis-targeting 2025-10-21T05:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-lirum-s-lx-101-for-inclusion-in-rapid-platform-trial-for-rare-pediatric-cancers 2025-10-21T01:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-lirum-s-lx-101-for-inclusion-in-rapid-platform-trial-for-rare-pediatric-cancers 2025-10-21T01:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/camrelizumab-famitinib-combination-demonstrates-superior-survival-outcomes-in-metastatic-cervical-cancer 2025-10-21T01:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camrelizumab-famitinib-combination-demonstrates-superior-survival-outcomes-in-metastatic-cervical-cancer 2025-10-21T01:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tirzepatide-for-obstructive-sleep-apnea-expanding-glp-1-therapy-access-beyond-diabetes 2025-10-21T01:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tirzepatide-for-obstructive-sleep-apnea-expanding-glp-1-therapy-access-beyond-diabetes 2025-10-21T01:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-reports-3-year-sustained-efficacy-data-for-pcrx-201-gene-therapy-in-knee-osteoarthritis 2025-10-21T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-biosciences-reports-3-year-sustained-efficacy-data-for-pcrx-201-gene-therapy-in-knee-osteoarthritis 2025-10-21T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/teva-partners-with-prestige-biopharma-to-commercialize-tuznue-trastuzumab-biosimilar-across-europe 2025-10-21T01:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-partners-with-prestige-biopharma-to-commercialize-tuznue-trastuzumab-biosimilar-across-europe 2025-10-21T01:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/rwanda-fda-approves-first-biosimilar-ranibizumab-in-africa-for-sight-threatening-eye-diseases 2025-10-21T01:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rwanda-fda-approves-first-biosimilar-ranibizumab-in-africa-for-sight-threatening-eye-diseases 2025-10-21T01:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-receives-ema-support-for-ycanth-european-approval-without-additional-phase-3-studies 2025-10-21T01:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-receives-ema-support-for-ycanth-european-approval-without-additional-phase-3-studies 2025-10-21T01:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/technology-partnership-announcement-knectiq-and-src-uk-licensing-agreement-for-defense-intelligence-platforms 2025-10-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/technology-partnership-announcement-knectiq-and-src-uk-licensing-agreement-for-defense-intelligence-platforms 2025-10-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-establishes-early-phase-center-of-excellence-to-streamline-biotech-clinical-development 2025-10-20T22:00:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avance-clinical-establishes-early-phase-center-of-excellence-to-streamline-biotech-clinical-development 2025-10-20T22:00:35+00:00 hourly 0.9 https://trial.medpath.com/news/judo-bio-demonstrates-sustained-kidney-selective-gene-silencing-with-megalin-striker-platform-across-species 2025-10-20T21:57:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/judo-bio-demonstrates-sustained-kidney-selective-gene-silencing-with-megalin-striker-platform-across-species 2025-10-20T21:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-drug-approval-rates-drop-to-73-as-review-delays-and-rejections-rise-in-q3 2025-10-20T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-drug-approval-rates-drop-to-73-as-review-delays-and-rejections-rise-in-q3 2025-10-20T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/faeth-therapeutics-raises-25m-to-advance-piktor-therapy-after-80-response-rate-in-endometrial-cancer 2025-10-20T21:52:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faeth-therapeutics-raises-25m-to-advance-piktor-therapy-after-80-response-rate-in-endometrial-cancer 2025-10-20T21:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-80-response-rate-in-first-in-human-melanoma-study 2025-10-20T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-80-response-rate-in-first-in-human-melanoma-study 2025-10-20T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/tigit-checkpoint-inhibitor-discovered-to-promote-tissue-healing-beyond-cancer-treatment 2025-10-20T21:51:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tigit-checkpoint-inhibitor-discovered-to-promote-tissue-healing-beyond-cancer-treatment 2025-10-20T21:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/bemarituzumab-plus-chemotherapy-shows-initial-overall-survival-benefit-in-fgfr2b-positive-gastric-cancer 2025-10-20T21:51:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bemarituzumab-plus-chemotherapy-shows-initial-overall-survival-benefit-in-fgfr2b-positive-gastric-cancer 2025-10-20T21:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-adc-companies-showcase-breakthrough-clinical-data-at-esmo-2025 2025-10-20T21:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-adc-companies-showcase-breakthrough-clinical-data-at-esmo-2025 2025-10-20T21:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/camrelizumab-famitinib-combination-shows-superior-survival-outcomes-in-phase-iii-cervical-cancer-trial 2025-10-20T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camrelizumab-famitinib-combination-shows-superior-survival-outcomes-in-phase-iii-cervical-cancer-trial 2025-10-20T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-reveals-two-year-natural-history-data-for-rare-eye-disease-adoa-supporting-phase-1-trial-of-stk-002 2025-10-20T21:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-reveals-two-year-natural-history-data-for-rare-eye-disease-adoa-supporting-phase-1-trial-of-stk-002 2025-10-20T21:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-appoints-rachael-lester-as-chief-business-officer-to-advance-probody-platform 2025-10-20T20:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-appoints-rachael-lester-as-chief-business-officer-to-advance-probody-platform 2025-10-20T20:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/prolong-pharmaceuticals-reports-promising-phase-1-2-results-for-pp-007-in-acute-ischemic-stroke 2025-10-20T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolong-pharmaceuticals-reports-promising-phase-1-2-results-for-pp-007-in-acute-ischemic-stroke 2025-10-20T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-s-cefiderocol-shows-superior-outcomes-when-used-as-early-treatment-for-drug-resistant-infections 2025-10-20T17:43:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-s-cefiderocol-shows-superior-outcomes-when-used-as-early-treatment-for-drug-resistant-infections 2025-10-20T17:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-refractory-autoimmune-diseases-in-first-in-human-trial 2025-10-20T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-refractory-autoimmune-diseases-in-first-in-human-trial 2025-10-20T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-doxycycline-in-canada-targeting-growing-antibiotic-market 2025-10-20T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-doxycycline-in-canada-targeting-growing-antibiotic-market 2025-10-20T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-advances-novel-glycan-targeted-adc-gnx1021-for-her2-low-gastric-cancer 2025-10-20T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glyconex-advances-novel-glycan-targeted-adc-gnx1021-for-her2-low-gastric-cancer 2025-10-20T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-pennsylvania-scientists-achieve-breakthrough-results-in-early-car-t-cell-therapy-trials-leading-to-kymriah-development 2025-10-20T17:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-pennsylvania-scientists-achieve-breakthrough-results-in-early-car-t-cell-therapy-trials-leading-to-kymriah-development 2025-10-20T17:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-advances-patent-protection-for-longevity-gene-therapy-platform 2025-10-20T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-advances-patent-protection-for-longevity-gene-therapy-platform 2025-10-20T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/rinvoq-demonstrates-superior-efficacy-over-humira-in-first-head-to-head-trial-for-tnf-inhibitor-experienced-rheumatoid-arthritis-patients 2025-10-20T17:30:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rinvoq-demonstrates-superior-efficacy-over-humira-in-first-head-to-head-trial-for-tnf-inhibitor-experienced-rheumatoid-arthritis-patients 2025-10-20T17:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-appoints-gene-therapy-expert-james-gow-as-senior-vp-of-clinical-development 2025-10-20T17:29:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-appoints-gene-therapy-expert-james-gow-as-senior-vp-of-clinical-development 2025-10-20T17:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/adarx-pharmaceuticals-to-present-phase-1-data-for-adx-038-sirna-therapy-at-asn-kidney-week-2025 2025-10-20T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adarx-pharmaceuticals-to-present-phase-1-data-for-adx-038-sirna-therapy-at-asn-kidney-week-2025 2025-10-20T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-rpt904-shows-comparable-efficacy-to-xolair-in-chronic-hives-trial 2025-10-20T17:28:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-rpt904-shows-comparable-efficacy-to-xolair-in-chronic-hives-trial 2025-10-20T17:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/valink-therapeutics-raises-11-8-million-to-advance-bispecific-adc-platform-for-cancer-treatment 2025-10-20T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valink-therapeutics-raises-11-8-million-to-advance-bispecific-adc-platform-for-cancer-treatment 2025-10-20T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/the-jackson-laboratory-acquires-new-york-stem-cell-foundation-to-accelerate-precision-medicine-discovery 2025-10-20T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-jackson-laboratory-acquires-new-york-stem-cell-foundation-to-accelerate-precision-medicine-discovery 2025-10-20T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-partners-with-x-chem-to-expand-hit-identification-capabilities-through-dna-encoded-library-technology 2025-10-20T17:26:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-partners-with-x-chem-to-expand-hit-identification-capabilities-through-dna-encoded-library-technology 2025-10-20T17:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-partners-with-redhill-to-co-commercialize-h-pylori-treatment-talicia 2025-10-20T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-partners-with-redhill-to-co-commercialize-h-pylori-treatment-talicia 2025-10-20T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/ogrd-alliance-expands-phospholipoproteomic-platform-across-asia-and-mena-regions 2025-10-20T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ogrd-alliance-expands-phospholipoproteomic-platform-across-asia-and-mena-regions 2025-10-20T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-receives-ema-authorization-to-begin-phase-1-trial-of-ax-0810-rna-editing-therapy-for-cholestatic-diseases 2025-10-20T17:24:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-receives-ema-authorization-to-begin-phase-1-trial-of-ax-0810-rna-editing-therapy-for-cholestatic-diseases 2025-10-20T17:24:19+00:00 hourly 0.9 https://trial.medpath.com/news/endo-launches-first-generic-version-of-ravicti-for-rare-urea-cycle-disorders 2025-10-20T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endo-launches-first-generic-version-of-ravicti-for-rare-urea-cycle-disorders 2025-10-20T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/citius-oncology-completes-distribution-network-for-lymphir-with-mckesson-partnership-ahead-of-q4-2025-launch 2025-10-20T17:23:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citius-oncology-completes-distribution-network-for-lymphir-with-mckesson-partnership-ahead-of-q4-2025-launch 2025-10-20T17:23:05+00:00 hourly 0.9 https://trial.medpath.com/news/oura-pursues-fda-clearance-for-blood-pressure-monitoring-feature-in-smart-ring 2025-10-20T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oura-pursues-fda-clearance-for-blood-pressure-monitoring-feature-in-smart-ring 2025-10-20T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-health-canada-approved-phase-2-trial-investigates-psilocybin-microdosing-for-generalized-anxiety-disorder 2025-10-20T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-health-canada-approved-phase-2-trial-investigates-psilocybin-microdosing-for-generalized-anxiety-disorder 2025-10-20T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-zanzalintinib-combination-shows-modest-survival-benefit-in-advanced-colorectal-cancer-trial 2025-10-20T17:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-zanzalintinib-combination-shows-modest-survival-benefit-in-advanced-colorectal-cancer-trial 2025-10-20T17:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/ibd-patients-face-elevated-risk-of-depression-and-anxiety-through-gut-brain-axis-dysfunction 2025-10-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibd-patients-face-elevated-risk-of-depression-and-anxiety-through-gut-brain-axis-dysfunction 2025-10-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sunrock-biopharma-partners-with-chime-biologics-to-advance-anti-ccr9-antibody-srb5-for-inflammatory-bowel-disease 2025-10-20T13:55:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunrock-biopharma-partners-with-chime-biologics-to-advance-anti-ccr9-antibody-srb5-for-inflammatory-bowel-disease 2025-10-20T13:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/weightwatchers-partners-with-amazon-pharmacy-to-expand-glp-1-obesity-treatment-access 2025-10-20T13:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weightwatchers-partners-with-amazon-pharmacy-to-expand-glp-1-obesity-treatment-access 2025-10-20T13:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/unc-scientists-engineer-dna-flower-robots-for-targeted-drug-delivery 2025-10-20T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unc-scientists-engineer-dna-flower-robots-for-targeted-drug-delivery 2025-10-20T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-therapeutics-initiates-first-in-human-car-t-trial-for-progressive-multiple-sclerosis 2025-10-20T13:46:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autolus-therapeutics-initiates-first-in-human-car-t-trial-for-progressive-multiple-sclerosis 2025-10-20T13:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researchers-overcome-aml-drug-resistance-with-novel-combination-therapy 2025-10-20T13:46:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-researchers-overcome-aml-drug-resistance-with-novel-combination-therapy 2025-10-20T13:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/stratifai-partners-with-memorial-sloan-kettering-to-validate-ai-powered-breast-cancer-biomarker-platform 2025-10-20T13:44:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stratifai-partners-with-memorial-sloan-kettering-to-validate-ai-powered-breast-cancer-biomarker-platform 2025-10-20T13:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/viridian-therapeutics-secures-300m-royalty-financing-to-advance-thyroid-eye-disease-therapies 2025-10-20T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viridian-therapeutics-secures-300m-royalty-financing-to-advance-thyroid-eye-disease-therapies 2025-10-20T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/cyclana-bio-secures-ps5m-to-pioneer-tissue-level-drug-discovery-for-endometriosis 2025-10-20T13:39:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclana-bio-secures-ps5m-to-pioneer-tissue-level-drug-discovery-for-endometriosis 2025-10-20T13:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/glaukos-receives-fda-approval-for-epioxa-first-incision-free-topical-therapy-for-keratoconus 2025-10-20T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glaukos-receives-fda-approval-for-epioxa-first-incision-free-topical-therapy-for-keratoconus 2025-10-20T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/merck-breaks-ground-on-3-billion-pharmaceutical-manufacturing-center-of-excellence-in-virginia 2025-10-20T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-breaks-ground-on-3-billion-pharmaceutical-manufacturing-center-of-excellence-in-virginia 2025-10-20T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharming-group-to-present-12-studies-on-rare-disease-treatments-at-2025-acaai-meeting 2025-10-20T10:50:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharming-group-to-present-12-studies-on-rare-disease-treatments-at-2025-acaai-meeting 2025-10-20T10:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-debuts-exhibition-booth-at-esmo-2025-with-46-oncology-studies-across-14-therapeutic-programs 2025-10-20T10:47:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharma-debuts-exhibition-booth-at-esmo-2025-with-46-oncology-studies-across-14-therapeutic-programs 2025-10-20T10:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/edx-medical-secures-ps4-million-funding-to-advance-cancer-diagnostic-pipeline 2025-10-20T10:44:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edx-medical-secures-ps4-million-funding-to-advance-cancer-diagnostic-pipeline 2025-10-20T10:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-s-first-biopharma-plant-launches-tirzepatide-for-type-2-diabetes-and-obesity 2025-10-20T10:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pakistan-s-first-biopharma-plant-launches-tirzepatide-for-type-2-diabetes-and-obesity 2025-10-20T10:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/neuren-pharmaceuticals-receives-fda-fast-track-designation-for-nnz-2591-in-rare-neurological-syndromes 2025-10-20T06:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuren-pharmaceuticals-receives-fda-fast-track-designation-for-nnz-2591-in-rare-neurological-syndromes 2025-10-20T06:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-satri-cel-shows-promising-results-in-world-s-first-car-t-cell-adjuvant-therapy-trial-for-pancreatic-cancer 2025-10-20T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-satri-cel-shows-promising-results-in-world-s-first-car-t-cell-adjuvant-therapy-trial-for-pancreatic-cancer 2025-10-20T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/monash-scientists-decode-rna-splicing-mechanisms-opening-path-to-personalized-mrna-therapies 2025-10-20T06:23:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monash-scientists-decode-rna-splicing-mechanisms-opening-path-to-personalized-mrna-therapies 2025-10-20T06:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-partners-with-openai-to-accelerate-drug-development-using-ai-technology 2025-10-20T06:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-partners-with-openai-to-accelerate-drug-development-using-ai-technology 2025-10-20T06:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/discus-trial-shows-3-cycles-of-chemotherapy-improve-quality-of-life-without-compromising-efficacy-in-advanced-urothelial-cancer 2025-10-20T06:22:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/discus-trial-shows-3-cycles-of-chemotherapy-improve-quality-of-life-without-compromising-efficacy-in-advanced-urothelial-cancer 2025-10-20T06:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharma-s-jskn003-receives-second-breakthrough-therapy-designation-in-china-for-her2-positive-colorectal-cancer 2025-10-20T06:17:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharma-s-jskn003-receives-second-breakthrough-therapy-designation-in-china-for-her2-positive-colorectal-cancer 2025-10-20T06:17:37+00:00 hourly 0.9 https://trial.medpath.com/news/kivu-bioscience-initiates-first-in-human-trial-of-kivu-107-next-generation-ptk7-targeting-adc-for-advanced-solid-tumors 2025-10-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kivu-bioscience-initiates-first-in-human-trial-of-kivu-107-next-generation-ptk7-targeting-adc-for-advanced-solid-tumors 2025-10-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dynamic-iii-trial-shows-promise-for-ctdna-guided-chemotherapy-de-escalation-in-stage-iii-colon-cancer 2025-10-20T03:41:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynamic-iii-trial-shows-promise-for-ctdna-guided-chemotherapy-de-escalation-in-stage-iii-colon-cancer 2025-10-20T03:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/clover-biopharmaceuticals-appoints-nicholas-jackson-as-president-of-global-r-d-to-advance-rsv-combination-vaccine-development 2025-10-20T03:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clover-biopharmaceuticals-appoints-nicholas-jackson-as-president-of-global-r-d-to-advance-rsv-combination-vaccine-development 2025-10-20T03:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-therapy-achieves-ctdna-clearance-in-26-of-colorectal-cancer-patients-improves-disease-free-survival 2025-10-19T21:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-therapy-achieves-ctdna-clearance-in-26-of-colorectal-cancer-patients-improves-disease-free-survival 2025-10-19T21:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-mixed-results-in-advanced-endometrial-cancer-trial-benefits-dmmr-patients 2025-10-19T21:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-shows-mixed-results-in-advanced-endometrial-cancer-trial-benefits-dmmr-patients 2025-10-19T21:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-complete-response-letter-to-xbrane-s-ranibizumab-biosimilar-application 2025-10-19T21:26:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-second-complete-response-letter-to-xbrane-s-ranibizumab-biosimilar-application 2025-10-19T21:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/dream3r-phase-3-trial-shows-promise-but-inconclusive-results-for-durvalumab-in-advanced-pleural-mesothelioma 2025-10-19T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dream3r-phase-3-trial-shows-promise-but-inconclusive-results-for-durvalumab-in-advanced-pleural-mesothelioma 2025-10-19T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/ioncologi-secures-key-patent-for-rna-based-cancer-immunotherapy-as-studies-link-covid-19-mrna-vaccines-to-enhanced-checkpoint-inhibitor-response 2025-10-19T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ioncologi-secures-key-patent-for-rna-based-cancer-immunotherapy-as-studies-link-covid-19-mrna-vaccines-to-enhanced-checkpoint-inhibitor-response 2025-10-19T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-expands-oncology-distribution-network-with-lymphir-and-phyrago-partnerships 2025-10-19T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mckesson-expands-oncology-distribution-network-with-lymphir-and-phyrago-partnerships 2025-10-19T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-flu-vaccines-show-promising-efficacy-and-safety-data-at-idweek-2025 2025-10-19T17:20:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-flu-vaccines-show-promising-efficacy-and-safety-data-at-idweek-2025 2025-10-19T17:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-s-ds-3939-shows-promising-early-results-in-advanced-solid-tumors-phase-1-2-trial 2025-10-19T17:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-s-ds-3939-shows-promising-early-results-in-advanced-solid-tumors-phase-1-2-trial 2025-10-19T17:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/avelumab-shows-modest-activity-in-advanced-penile-cancer-but-fails-to-deliver-transformative-survival-benefits 2025-10-19T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avelumab-shows-modest-activity-in-advanced-penile-cancer-but-fails-to-deliver-transformative-survival-benefits 2025-10-19T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/wuhan-yzy-biopharma-s-m701-shows-superior-efficacy-over-cisplatin-in-phase-ii-trial-for-malignant-pleural-effusion 2025-10-19T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuhan-yzy-biopharma-s-m701-shows-superior-efficacy-over-cisplatin-in-phase-ii-trial-for-malignant-pleural-effusion 2025-10-19T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/capivasertib-shows-significant-survival-benefit-in-pten-deficient-metastatic-prostate-cancer 2025-10-19T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capivasertib-shows-significant-survival-benefit-in-pten-deficient-metastatic-prostate-cancer 2025-10-19T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-prepares-to-release-phase-2-data-for-rpt904-in-chronic-spontaneous-urticaria 2025-10-19T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-prepares-to-release-phase-2-data-for-rpt904-in-chronic-spontaneous-urticaria 2025-10-19T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-rybrevant-shows-45-response-rate-in-head-and-neck-cancer-doubling-standard-of-care 2025-10-19T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-rybrevant-shows-45-response-rate-in-head-and-neck-cancer-doubling-standard-of-care 2025-10-19T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-amivantamab-shows-45-response-rate-in-recurrent-head-and-neck-cancer 2025-10-19T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-amivantamab-shows-45-response-rate-in-recurrent-head-and-neck-cancer 2025-10-19T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-cancer-vaccines-show-promise-for-pancreatic-cancer-treatment-despite-immunosuppressive-challenges 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-cancer-vaccines-show-promise-for-pancreatic-cancer-treatment-despite-immunosuppressive-challenges 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nanomaterial-enhanced-mri-reveals-novel-biomarkers-for-hepatocellular-carcinoma-diagnosis-and-therapy 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanomaterial-enhanced-mri-reveals-novel-biomarkers-for-hepatocellular-carcinoma-diagnosis-and-therapy 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-braftovi-plus-mektovi-achieves-nearly-four-year-survival-in-braf-mutant-lung-cancer 2025-10-19T14:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-braftovi-plus-mektovi-achieves-nearly-four-year-survival-in-braf-mutant-lung-cancer 2025-10-19T14:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-covid-19-vaccines-show-promise-in-enhancing-cancer-immunotherapy-survival-rates 2025-10-19T14:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-covid-19-vaccines-show-promise-in-enhancing-cancer-immunotherapy-survival-rates 2025-10-19T14:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-immunization-safe-for-infants-regardless-of-maternal-vaccination-status-new-study-shows 2025-10-19T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-immunization-safe-for-infants-regardless-of-maternal-vaccination-status-new-study-shows 2025-10-19T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-allogeneic-bcma-car-t-therapy-ct0596-shows-promising-results-in-rare-primary-plasma-cell-leukemia 2025-10-19T09:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-allogeneic-bcma-car-t-therapy-ct0596-shows-promising-results-in-rare-primary-plasma-cell-leukemia 2025-10-19T09:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/leap-014-trial-shows-lenvatinib-triple-combination-fails-to-improve-survival-in-metastatic-esophageal-cancer 2025-10-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-014-trial-shows-lenvatinib-triple-combination-fails-to-improve-survival-in-metastatic-esophageal-cancer 2025-10-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-demonstrates-safety-and-efficacy-of-epithelium-on-corneal-cross-linking-for-keratoconus-treatment 2025-10-19T01:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-demonstrates-safety-and-efficacy-of-epithelium-on-corneal-cross-linking-for-keratoconus-treatment 2025-10-19T01:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/cork-biotech-arraypatch-wins-eur800k-seedcorn-award-for-revolutionary-microneedle-drug-delivery-technology 2025-10-19T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cork-biotech-arraypatch-wins-eur800k-seedcorn-award-for-revolutionary-microneedle-drug-delivery-technology 2025-10-19T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/cadonilimab-plus-chemotherapy-demonstrates-sustained-survival-benefit-in-advanced-gastric-cancer-final-analysis 2025-10-19T01:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadonilimab-plus-chemotherapy-demonstrates-sustained-survival-benefit-in-advanced-gastric-cancer-final-analysis 2025-10-19T01:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/aurion-biotech-s-aurn001-cell-therapy-achieves-all-endpoints-in-phase-1-2-trial-for-corneal-endothelial-disease 2025-10-18T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurion-biotech-s-aurn001-cell-therapy-achieves-all-endpoints-in-phase-1-2-trial-for-corneal-endothelial-disease 2025-10-18T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-eyes-full-acquisition-of-protagonist-therapeutics-following-successful-icotrokinra-partnership 2025-10-18T21:25:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-eyes-full-acquisition-of-protagonist-therapeutics-following-successful-icotrokinra-partnership 2025-10-18T21:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/il33-st2-axis-emerges-as-predictive-biomarker-for-anti-pd1-therapy-in-advanced-gastric-cancer 2025-10-18T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il33-st2-axis-emerges-as-predictive-biomarker-for-anti-pd1-therapy-in-advanced-gastric-cancer 2025-10-18T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/taysha-gene-therapies-faces-mounting-financial-pressure-amid-leadership-changes-and-operational-challenges 2025-10-18T21:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taysha-gene-therapies-faces-mounting-financial-pressure-amid-leadership-changes-and-operational-challenges 2025-10-18T21:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/xtr008-achieves-dramatic-progression-free-survival-benefit-in-advanced-gastroenteropancreatic-neuroendocrine-tumors 2025-10-18T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtr008-achieves-dramatic-progression-free-survival-benefit-in-advanced-gastroenteropancreatic-neuroendocrine-tumors 2025-10-18T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/invikafusp-alfa-shows-promise-in-checkpoint-inhibitor-resistant-solid-tumors-with-high-disease-control-rates 2025-10-18T21:20:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invikafusp-alfa-shows-promise-in-checkpoint-inhibitor-resistant-solid-tumors-with-high-disease-control-rates 2025-10-18T21:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-monoclonal-antibody-mam01-demonstrates-complete-protection-against-malaria-in-phase-1-trial 2025-10-18T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-monoclonal-antibody-mam01-demonstrates-complete-protection-against-malaria-in-phase-1-trial 2025-10-18T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/y-ora-vision-launches-with-novel-migs-device-for-glaucoma-treatment-following-seri-eyexora-licensing-deal 2025-10-18T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-ora-vision-launches-with-novel-migs-device-for-glaucoma-treatment-following-seri-eyexora-licensing-deal 2025-10-18T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-mrna-4359-as-late-stage-oncology-asset-with-new-melanoma-data 2025-10-18T17:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-mrna-4359-as-late-stage-oncology-asset-with-new-melanoma-data 2025-10-18T17:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/scg142-demonstrates-100-disease-control-rate-in-first-in-human-trial-for-hpv-associated-cancers 2025-10-18T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scg142-demonstrates-100-disease-control-rate-in-first-in-human-trial-for-hpv-associated-cancers 2025-10-18T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/keytruda-plus-lenvima-shows-durable-5-year-survival-benefit-in-advanced-endometrial-cancer 2025-10-18T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keytruda-plus-lenvima-shows-durable-5-year-survival-benefit-in-advanced-endometrial-cancer 2025-10-18T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/vimseltinib-shows-durable-two-year-efficacy-in-tenosynovial-giant-cell-tumor-phase-3-trial 2025-10-18T17:18:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vimseltinib-shows-durable-two-year-efficacy-in-tenosynovial-giant-cell-tumor-phase-3-trial 2025-10-18T17:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/india-develops-first-indigenous-antibiotic-nafithromycin-for-resistant-respiratory-infections 2025-10-18T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-develops-first-indigenous-antibiotic-nafithromycin-for-resistant-respiratory-infections 2025-10-18T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-iron-based-contrast-agent-for-brain-mri-imaging 2025-10-18T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-iron-based-contrast-agent-for-brain-mri-imaging 2025-10-18T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/topical-vaginal-drug-therapy-shows-promise-as-novel-cervical-cancer-treatment-approach 2025-10-18T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-vaginal-drug-therapy-shows-promise-as-novel-cervical-cancer-treatment-approach 2025-10-18T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-reports-promising-phase-1-results-for-gedatolisib-darolutamide-combination-in-metastatic-prostate-cancer 2025-10-18T13:41:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celcuity-reports-promising-phase-1-results-for-gedatolisib-darolutamide-combination-in-metastatic-prostate-cancer 2025-10-18T13:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/precede-biosciences-unveils-liquid-biopsy-platform-for-small-cell-lung-cancer-target-expression-at-esmo-2025 2025-10-18T13:40:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precede-biosciences-unveils-liquid-biopsy-platform-for-small-cell-lung-cancer-target-expression-at-esmo-2025 2025-10-18T13:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/salubris-biotherapeutics-reports-promising-phase-1-results-for-5t4-targeted-adc-jk06-in-advanced-solid-tumors 2025-10-18T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salubris-biotherapeutics-reports-promising-phase-1-results-for-5t4-targeted-adc-jk06-in-advanced-solid-tumors 2025-10-18T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-nx-1607-shows-49-3-disease-control-rate-in-first-in-class-cbl-b-inhibitor-trial 2025-10-18T13:39:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-nx-1607-shows-49-3-disease-control-rate-in-first-in-class-cbl-b-inhibitor-trial 2025-10-18T13:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/pherflot-trial-achieves-48-complete-response-rate-in-her2-positive-gastric-cancer 2025-10-18T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pherflot-trial-achieves-48-complete-response-rate-in-her2-positive-gastric-cancer 2025-10-18T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-hansoh-s-cdh17-targeting-adc-hs-20110-in-1-45-billion-deal 2025-10-18T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-acquires-hansoh-s-cdh17-targeting-adc-hs-20110-in-1-45-billion-deal 2025-10-18T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/doxypep-shows-mixed-results-against-stis-as-resistance-concerns-mount-in-clinical-studies 2025-10-18T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doxypep-shows-mixed-results-against-stis-as-resistance-concerns-mount-in-clinical-studies 2025-10-18T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-director-takes-direct-control-of-patent-challenge-reviews-potentially-strengthening-patent-protection 2025-10-18T09:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-director-takes-direct-control-of-patent-challenge-reviews-potentially-strengthening-patent-protection 2025-10-18T09:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/lenvatinib-everolimus-combination-outperforms-cabozantinib-in-second-line-kidney-cancer-treatment 2025-10-18T09:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenvatinib-everolimus-combination-outperforms-cabozantinib-in-second-line-kidney-cancer-treatment 2025-10-18T09:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/rituximab-shows-promise-for-treatment-resistant-hypersensitivity-pneumonitis-in-new-study 2025-10-18T00:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rituximab-shows-promise-for-treatment-resistant-hypersensitivity-pneumonitis-in-new-study 2025-10-18T00:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/ponsegromab-shows-sustained-weight-gain-in-cancer-cachexia-patients-over-64-week-extension-study 2025-10-18T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ponsegromab-shows-sustained-weight-gain-in-cancer-cachexia-patients-over-64-week-extension-study 2025-10-18T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-secures-11m-funding-to-advance-heart-disease-pipeline-following-breakthrough-archer-trial-results 2025-10-18T00:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiol-therapeutics-secures-11m-funding-to-advance-heart-disease-pipeline-following-breakthrough-archer-trial-results 2025-10-18T00:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-consortium-develops-digital-endpoint-for-atopic-dermatitis-clinical-trials 2025-10-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-consortium-develops-digital-endpoint-for-atopic-dermatitis-clinical-trials 2025-10-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rutgers-scientists-identify-mitochondrial-mechanism-behind-venetoclax-resistance-in-acute-myeloid-leukemia 2025-10-17T22:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rutgers-scientists-identify-mitochondrial-mechanism-behind-venetoclax-resistance-in-acute-myeloid-leukemia 2025-10-17T22:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/silver-creek-pharmaceuticals-receives-fda-fast-track-designation-for-novel-stroke-therapy-scp776 2025-10-17T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silver-creek-pharmaceuticals-receives-fda-fast-track-designation-for-novel-stroke-therapy-scp776 2025-10-17T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-s-dna-vaccine-shows-superior-durability-over-mrna-vaccines-in-phase-1-covid-19-trial 2025-10-17T22:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-s-dna-vaccine-shows-superior-durability-over-mrna-vaccines-in-phase-1-covid-19-trial 2025-10-17T22:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/zongertinib-shows-77-response-rate-in-first-line-treatment-of-her2-mutant-lung-cancer 2025-10-17T22:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zongertinib-shows-77-response-rate-in-first-line-treatment-of-her2-mutant-lung-cancer 2025-10-17T22:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/serum-cd80-emerges-as-predictive-biomarker-for-neoadjuvant-immunotherapy-response-in-esophageal-cancer 2025-10-17T22:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serum-cd80-emerges-as-predictive-biomarker-for-neoadjuvant-immunotherapy-response-in-esophageal-cancer 2025-10-17T22:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-of-checkpoint-inhibitor-pneumonitis-reveals-key-risk-factors-and-management-patterns-across-25-nivolumab-trials 2025-10-17T21:57:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-analysis-of-checkpoint-inhibitor-pneumonitis-reveals-key-risk-factors-and-management-patterns-across-25-nivolumab-trials 2025-10-17T21:57:41+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-reports-1-27-million-q3-licensing-revenue-as-cns-pipeline-advances-toward-phase-iii 2025-10-17T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvc-biopharma-reports-1-27-million-q3-licensing-revenue-as-cns-pipeline-advances-toward-phase-iii 2025-10-17T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-to-present-phase-2-rally-mf-trial-data-for-disc-0974-in-myelofibrosis-associated-anemia-at-ash-2025 2025-10-17T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-to-present-phase-2-rally-mf-trial-data-for-disc-0974-in-myelofibrosis-associated-anemia-at-ash-2025 2025-10-17T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/dovato-demonstrates-non-inferior-efficacy-to-biktarvy-with-significantly-less-weight-gain-in-96-week-hiv-treatment-study 2025-10-17T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dovato-demonstrates-non-inferior-efficacy-to-biktarvy-with-significantly-less-weight-gain-in-96-week-hiv-treatment-study 2025-10-17T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/corvus-pharmaceuticals-reports-promising-interim-data-for-ciforadenant-triple-therapy-in-metastatic-renal-cell-cancer 2025-10-17T17:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-reports-promising-interim-data-for-ciforadenant-triple-therapy-in-metastatic-renal-cell-cancer 2025-10-17T17:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-biotherapeutics-receives-fda-fast-track-designation-for-allonk-cell-therapy-in-refractory-rheumatoid-arthritis 2025-10-17T17:23:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-biotherapeutics-receives-fda-fast-track-designation-for-allonk-cell-therapy-in-refractory-rheumatoid-arthritis 2025-10-17T17:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-alban-trial-shows-atezolizumab-plus-bcg-fails-to-improve-outcomes-in-high-risk-bladder-cancer 2025-10-17T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-alban-trial-shows-atezolizumab-plus-bcg-fails-to-improve-outcomes-in-high-risk-bladder-cancer 2025-10-17T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/itm-to-present-phase-3-compete-trial-subgroup-analyses-at-nanets-2025-highlighting-177lu-edotreotide-success-in-gep-nets 2025-10-17T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-to-present-phase-3-compete-trial-subgroup-analyses-at-nanets-2025-highlighting-177lu-edotreotide-success-in-gep-nets 2025-10-17T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/ucl-scientists-engineer-gdt-cells-to-target-chemotherapy-resistant-bowel-cancer 2025-10-17T17:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucl-scientists-engineer-gdt-cells-to-target-chemotherapy-resistant-bowel-cancer 2025-10-17T17:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-gene-therapy-shows-remarkable-success-in-treating-inherited-deafness 2025-10-17T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-gene-therapy-shows-remarkable-success-in-treating-inherited-deafness 2025-10-17T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/pimicotinib-shows-deepening-tumor-responses-in-tgct-patients-with-76-2-response-rate-at-extended-follow-up 2025-10-17T17:21:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pimicotinib-shows-deepening-tumor-responses-in-tgct-patients-with-76-2-response-rate-at-extended-follow-up 2025-10-17T17:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-kiniksa-s-kpl-387-for-pericarditis-treatment 2025-10-17T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-kiniksa-s-kpl-387-for-pericarditis-treatment 2025-10-17T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/multitude-therapeutics-reports-promising-phase-i-ii-results-for-cd44v9-directed-adc-amt-116-in-advanced-solid-tumors 2025-10-17T17:18:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multitude-therapeutics-reports-promising-phase-i-ii-results-for-cd44v9-directed-adc-amt-116-in-advanced-solid-tumors 2025-10-17T17:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/pin1-inhibitors-demonstrate-novel-antiviral-mechanism-against-hsv-1-by-trapping-virus-in-cell-nucleus 2025-10-17T17:16:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pin1-inhibitors-demonstrate-novel-antiviral-mechanism-against-hsv-1-by-trapping-virus-in-cell-nucleus 2025-10-17T17:16:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-sir-spheres-y-90-resin-microspheres-for-unresectable-hepatocellular-carcinoma 2025-10-17T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-sir-spheres-y-90-resin-microspheres-for-unresectable-hepatocellular-carcinoma 2025-10-17T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-promising-preclinical-data-for-tnx-801-mpox-vaccine-at-world-vaccine-congress 2025-10-17T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-reports-promising-preclinical-data-for-tnx-801-mpox-vaccine-at-world-vaccine-congress 2025-10-17T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-to-acquire-nalu-medical-for-533-million-expanding-peripheral-nerve-stimulation-portfolio 2025-10-17T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-to-acquire-nalu-medical-for-533-million-expanding-peripheral-nerve-stimulation-portfolio 2025-10-17T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-reject-sanofi-s-rezurock-for-chronic-graft-vs-host-disease-treatment 2025-10-17T14:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-reject-sanofi-s-rezurock-for-chronic-graft-vs-host-disease-treatment 2025-10-17T14:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-achieves-first-ever-clinical-success-targeting-undruggable-b-catenin-tcf-interaction-with-fog-001 2025-10-17T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabilis-medicines-achieves-first-ever-clinical-success-targeting-undruggable-b-catenin-tcf-interaction-with-fog-001 2025-10-17T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-pediatric-indications-for-yuflyma-biosimilar-extending-treatment-options-for-adolescent-hidradenitis-suppurativa-and-pediatric-uveitis 2025-10-17T13:52:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expanded-pediatric-indications-for-yuflyma-biosimilar-extending-treatment-options-for-adolescent-hidradenitis-suppurativa-and-pediatric-uveitis 2025-10-17T13:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/ema-rejects-extended-dosing-regimen-for-fabry-disease-treatment-elfabrio 2025-10-17T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-rejects-extended-dosing-regimen-for-fabry-disease-treatment-elfabrio 2025-10-17T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-dpyd-genetic-testing-before-capecitabine-chemotherapy-to-prevent-fatal-toxicity 2025-10-17T09:19:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-dpyd-genetic-testing-before-capecitabine-chemotherapy-to-prevent-fatal-toxicity 2025-10-17T09:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-pharmaceuticals-receives-positive-ema-opinion-for-sugemalimab-in-stage-iii-nsclc 2025-10-17T09:17:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-pharmaceuticals-receives-positive-ema-opinion-for-sugemalimab-in-stage-iii-nsclc 2025-10-17T09:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-long-acting-hiv-prevention-injection-for-england-and-wales 2025-10-17T09:16:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-long-acting-hiv-prevention-injection-for-england-and-wales 2025-10-17T09:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-rinvoq-becomes-first-oral-jak-inhibitor-approved-for-giant-cell-arteritis-as-novartis-cosentyx-fails-phase-iii-trial 2025-10-17T05:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-rinvoq-becomes-first-oral-jak-inhibitor-approved-for-giant-cell-arteritis-as-novartis-cosentyx-fails-phase-iii-trial 2025-10-17T05:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/dompe-receives-fda-priority-voucher-for-intranasal-ngf-therapy-targeting-naion-vision-loss 2025-10-17T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dompe-receives-fda-priority-voucher-for-intranasal-ngf-therapy-targeting-naion-vision-loss 2025-10-17T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-invests-110-million-in-grail-to-bring-multi-cancer-blood-test-to-asia 2025-10-17T05:16:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-invests-110-million-in-grail-to-bring-multi-cancer-blood-test-to-asia 2025-10-17T05:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-announces-strategic-transformation-to-novabridge-biosciences-with-hong-kong-ipo-plans-and-vis-101-acquisition 2025-10-17T01:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-announces-strategic-transformation-to-novabridge-biosciences-with-hong-kong-ipo-plans-and-vis-101-acquisition 2025-10-17T01:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-second-generic-mifepristone-despite-political-opposition 2025-10-17T01:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-second-generic-mifepristone-despite-political-opposition 2025-10-17T01:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-secures-deal-with-emd-serono-to-cut-fertility-drug-prices-by-up-to-84 2025-10-17T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-secures-deal-with-emd-serono-to-cut-fertility-drug-prices-by-up-to-84 2025-10-17T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-s-allonk-receives-fda-fast-track-designation-for-refractory-rheumatoid-arthritis 2025-10-17T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-s-allonk-receives-fda-fast-track-designation-for-refractory-rheumatoid-arthritis 2025-10-17T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/large-french-study-confirms-mrna-covid-19-vaccines-safe-during-early-pregnancy-no-increased-birth-defect-risk 2025-10-17T01:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-french-study-confirms-mrna-covid-19-vaccines-safe-during-early-pregnancy-no-increased-birth-defect-risk 2025-10-17T01:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunai-and-astrazeneca-expand-partnership-with-85m-ibd-target-discovery-deal 2025-10-17T01:17:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunai-and-astrazeneca-expand-partnership-with-85m-ibd-target-discovery-deal 2025-10-17T01:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-researcher-develops-ai-framework-to-overcome-drug-discovery-generalization-challenge 2025-10-17T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanderbilt-researcher-develops-ai-framework-to-overcome-drug-discovery-generalization-challenge 2025-10-17T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/dna-based-sensor-enables-5-minute-drug-monitoring-from-single-blood-drop-at-home 2025-10-17T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-based-sensor-enables-5-minute-drug-monitoring-from-single-blood-drop-at-home 2025-10-17T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-bpl-003-nasal-spray-for-treatment-resistant-depression 2025-10-17T01:15:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-bpl-003-nasal-spray-for-treatment-resistant-depression 2025-10-17T01:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/kezar-life-sciences-faces-fda-setback-for-autoimmune-hepatitis-drug-explores-strategic-alternatives 2025-10-16T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kezar-life-sciences-faces-fda-setback-for-autoimmune-hepatitis-drug-explores-strategic-alternatives 2025-10-16T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-receives-usan-approval-for-pevifoscorvir-sodium-first-generic-name-for-hepatitis-b-drug-candidate 2025-10-16T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-receives-usan-approval-for-pevifoscorvir-sodium-first-generic-name-for-hepatitis-b-drug-candidate 2025-10-16T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/california-launches-first-state-branded-insulin-program-offering-55-five-pack-to-combat-high-drug-costs 2025-10-16T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-launches-first-state-branded-insulin-program-offering-55-five-pack-to-combat-high-drug-costs 2025-10-16T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-safety-alert-on-radiofrequency-microneedling-devices-following-reports-of-severe-complications 2025-10-16T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-safety-alert-on-radiofrequency-microneedling-devices-following-reports-of-severe-complications 2025-10-16T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/allergy-therapeutics-reports-positive-progress-in-phase-2a-trial-of-vlp-peanut-allergy-vaccine 2025-10-16T21:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergy-therapeutics-reports-positive-progress-in-phase-2a-trial-of-vlp-peanut-allergy-vaccine 2025-10-16T21:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-reports-promising-phase-1-results-for-lasme-cel-in-relapsed-refractory-b-all-advances-to-pivotal-phase-2 2025-10-16T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectis-reports-promising-phase-1-results-for-lasme-cel-in-relapsed-refractory-b-all-advances-to-pivotal-phase-2 2025-10-16T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/thymic-health-emerges-as-novel-biomarker-for-predicting-immunotherapy-response-across-cancer-types 2025-10-16T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thymic-health-emerges-as-novel-biomarker-for-predicting-immunotherapy-response-across-cancer-types 2025-10-16T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-biopharma-secures-sek-60-million-conditional-financing-ahead-of-lucamzi-fda-decision 2025-10-16T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xbrane-biopharma-secures-sek-60-million-conditional-financing-ahead-of-lucamzi-fda-decision 2025-10-16T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/extended-release-oral-minoxidil-shows-promise-as-first-fda-approved-hair-loss-treatment-for-women 2025-10-16T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-release-oral-minoxidil-shows-promise-as-first-fda-approved-hair-loss-treatment-for-women 2025-10-16T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-proposes-major-restrictions-on-inter-partes-review-patent-challenges 2025-10-16T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-proposes-major-restrictions-on-inter-partes-review-patent-challenges 2025-10-16T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-systems-and-openevidence-partner-to-launch-ai-powered-clinical-trial-access-platform 2025-10-16T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeva-systems-and-openevidence-partner-to-launch-ai-powered-clinical-trial-access-platform 2025-10-16T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-achieves-95-success-rate-in-treating-ada-scid-bubble-boy-disease 2025-10-16T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-achieves-95-success-rate-in-treating-ada-scid-bubble-boy-disease 2025-10-16T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-secures-5-million-financing-to-advance-novel-adc-platform-with-spliceosome-modulator-payload 2025-10-16T17:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-secures-5-million-financing-to-advance-novel-adc-platform-with-spliceosome-modulator-payload 2025-10-16T17:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/bridgene-biosciences-secures-28-million-series-b-funding-to-advance-tead-inhibitor-bgc-515-toward-phase-2 2025-10-16T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgene-biosciences-secures-28-million-series-b-funding-to-advance-tead-inhibitor-bgc-515-toward-phase-2 2025-10-16T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-launches-direct-to-patient-program-for-xofluza-offering-70-price-reduction 2025-10-16T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-launches-direct-to-patient-program-for-xofluza-offering-70-price-reduction 2025-10-16T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-secures-exclusive-license-for-cd22-nanobody-technology-to-advance-next-generation-car-cell-therapies 2025-10-16T17:21:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-therapeutics-secures-exclusive-license-for-cd22-nanobody-technology-to-advance-next-generation-car-cell-therapies 2025-10-16T17:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-pharmaceutical-exercises-option-for-casdatifan-hif-2a-inhibitor-in-asia-pacific-territories 2025-10-16T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-pharmaceutical-exercises-option-for-casdatifan-hif-2a-inhibitor-in-asia-pacific-territories 2025-10-16T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/first-parkinson-s-patient-shows-significant-motor-improvement-with-ux-da001-autologous-cell-therapy 2025-10-16T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-parkinson-s-patient-shows-significant-motor-improvement-with-ux-da001-autologous-cell-therapy 2025-10-16T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-plan-fda-application-for-groundbreaking-crispr-base-editing-trial-following-baby-kj-s-successful-treatment 2025-10-16T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-plan-fda-application-for-groundbreaking-crispr-base-editing-trial-following-baby-kj-s-successful-treatment 2025-10-16T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-appoints-alpha-therapy-pioneer-andrew-kay-as-board-chair-to-lead-psma-targeted-radiopharmaceutical-development 2025-10-16T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-appoints-alpha-therapy-pioneer-andrew-kay-as-board-chair-to-lead-psma-targeted-radiopharmaceutical-development 2025-10-16T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-advances-esp-2001-for-primary-sclerosing-cholangitis-targeting-1-billion-market-opportunity 2025-10-16T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-advances-esp-2001-for-primary-sclerosing-cholangitis-targeting-1-billion-market-opportunity 2025-10-16T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/us-orphan-drug-market-poised-to-exceed-190-billion-by-2030-as-fda-designations-accelerate-rare-disease-therapy-development 2025-10-16T17:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-orphan-drug-market-poised-to-exceed-190-billion-by-2030-as-fda-designations-accelerate-rare-disease-therapy-development 2025-10-16T17:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/calico-appoints-former-abbvie-executive-philip-kym-as-head-of-drug-discovery-to-advance-anti-aging-therapeutics 2025-10-16T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calico-appoints-former-abbvie-executive-philip-kym-as-head-of-drug-discovery-to-advance-anti-aging-therapeutics 2025-10-16T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/doron-therapeutics-initiates-phase-3-trial-of-motys-biologic-therapy-for-knee-osteoarthritis 2025-10-16T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doron-therapeutics-initiates-phase-3-trial-of-motys-biologic-therapy-for-knee-osteoarthritis 2025-10-16T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/news/imbria-pharmaceuticals-partners-with-patient-advocacy-group-to-accelerate-recruitment-for-novel-heart-disease-trial 2025-10-16T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imbria-pharmaceuticals-partners-with-patient-advocacy-group-to-accelerate-recruitment-for-novel-heart-disease-trial 2025-10-16T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-pravastatin-in-canada-through-nora-pharma-subsidiary 2025-10-16T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-pravastatin-in-canada-through-nora-pharma-subsidiary 2025-10-16T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/senescent-immune-cells-drive-immunotherapy-resistance-in-cancer-through-sasp-mediated-tumor-microenvironment-remodeling 2025-10-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senescent-immune-cells-drive-immunotherapy-resistance-in-cancer-through-sasp-mediated-tumor-microenvironment-remodeling 2025-10-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/foghorn-therapeutics-reports-breakthrough-progress-in-selective-arid1b-degrader-for-cancer-treatment 2025-10-16T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foghorn-therapeutics-reports-breakthrough-progress-in-selective-arid1b-degrader-for-cancer-treatment 2025-10-16T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-hld-0915-shows-promising-first-in-human-results-in-advanced-prostate-cancer 2025-10-16T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-hld-0915-shows-promising-first-in-human-results-in-advanced-prostate-cancer 2025-10-16T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/google-deepmind-s-ai-model-discovers-novel-cancer-immunotherapy-approach-through-cell-level-analysis 2025-10-16T13:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-deepmind-s-ai-model-discovers-novel-cancer-immunotherapy-approach-through-cell-level-analysis 2025-10-16T13:20:55+00:00 hourly 0.9